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Introduction- Familial Hypercholesterolemia (FH) is a common genetic 
disease that is inherited in an autosomal dominant manner.  FH can be 
caused by mutations in the low-density lipoprotein receptor gene (LDLR) in  
80% of cases, in its main ligand apolipoprotein B gene (ApoB-100) in 5% of 
cases, in the propotein convertase subtilin/kexin type 9 gene (PCSK9),  an 
enzyme involved in LDLR degradation, in  1-2% of cases, while the genetic 
alteration is  still unidentified in 15% of cases.   
FH leads to premature coronary heart disease(CHD), namely myocardial 
infarction and angina pectoris, due to elevated plasma low-density 
lipoprotein cholesterol (LDL-C) levels and high levels of total cholesterol 
(TC).  
About 1 in 500 individuals in the  general population is affected, making it 
the most common monogenic form of hypercholesterolemia. Patients with 
homozygous alleles for defective LDLR are very rare, the frequency is 
about 1:106. 
Three scientific groups have developed diagnostic tools for FH: The US 
MedPed Program (Make Early Diagnosis, Prevent Early Death), the Simon 
Broome Register Group in the United Kingdom , and the Dutch Lipid Clinic 
Network (DLCNC). The major difference between these systems is the use 
of different cut-offs for premature CHD. 
The US MedPed Program based on validated age and sex adjusted for 
serum cholesterol cut-off points. The Simon Broome criteria take into 
account that TC and LDL-C levels differ for adults and children. The criteria 
also take into account of evidence of dominant transmission and the age of 
onset of coronary disease in the kindred. Using this approach, cases are 
categorized as ‘definite’ and ‘possible’. The DLCNC score is based on a 
family history of hypercholesterolemia, premature CHD, clinical features, 
LDL-C levels and DNA analysis. It uses a numeric score for each criterion, 
and classifies individuals as “definite”, “probable” or “possible” FH. A 
diagnosis is considered definite if the score is greater than 8, considered 
probable if the score is between 6 and 8 points, and considered possible 
when the score is between 3 and 5 points.  
Aims- To determine the frequency  and spectrum of mutations causing  FH 
in patients attending the different Italian lipid clinics. To investigate 
genotype-phenotype correlations in FH carrying different mutations of the 
LDL-R gene. To identify the  presence of a likely polygenic cause due to the 
inheritance of LDL-C-raising SNPs. In addition, to  evaluate which of 
diagnostic criteria DCLN or Simon Broome is more accurate to detect 
patients with mutations in our population. 
Results- Mutations were found in 214/322 subjects with a mutation rate of 
66%. Out of 214 mutated subjects about 95.3% were carriers of LDLR 
mutations, 2.8% of APOB mutations and 1.8% of PCSK9 mutations. In the 
LDLR gene we found 58 different mutations of which 5 were novels 
(c.102C>A; c.892A>G; c.1277T>G; c.694+1G>C c.1070_1071dupAG). 
Regarding the APOB gene we identified four different mutations of which 
two novels (p.Val3306Ile and p.Trp3633Arg ). 
In the PCSK9 gene we found four different variations of which two novels 
(p.Pro331Ala, p.Arg499Hys). The gradually increase of the TC and LDL-C 
among patients with different types of mutation shows  that  the type of the 
LDLR mutation influences the lipid profile. Patients with radical mutations 
show a worse lipid profile than missense carriers allowing a prognostic 
evaluation for physicians. In a proportion of patients with the FH phenotype 
but without mutations in the main candidate genes, there is a likely 
polygenic cause due to the inheritance of LDL-C-raising SNPs which 
increases LDL-C concentration in patients.  
In addition, we examined the reliability of the Dutch Lipid Clinic Network 
(DCLN) score and Simon Broome criteria, to identify patients with a high or 
low probability of carrying an FH-causing mutation. The DCLN criteria was 
more accurate than Simon Broom showing very high sensitivity and 
specificity to detect patients with mutations.  
Conclusions- The results of this study represent an update of FH genetic 
background in an Italian population of patients from southern regions. 
These data enlarge the spectrum of mutations causing FH. The correlation 
between mutation types and lipid profile underlines importance of genetic 
screening as  a prognostic tool. The comparison of the Dutch Lipid Clinic 
Network (DCLN) score and Simon Broome revealed that genetic screening 
is also useful to confirm the diagnosis, especially in patients with an 
uncertain phenotype. 
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 Riassunto 
 
L’Ipercolesterolemia Familiare (FH) è una malattia ereditaria, caratterizzata 
da un alterato metabolismo lipoproteico, che coinvolge quasi 
esclusivamente la frazione delle lipoproteine a bassa densità (Low Density 
Lipoprotein – LDL).  
L’Ipercolesterolemia Familiare (FH) è una patologia ereditaria, 
caratterizzata da un alterato metabolismo lipoproteico, che coinvolge quasi 
esclusivamente la frazione delle lipoproteine a bassa densità (Low Density 
Lipoprotein – LDL). 
La forma più comune di trasmissione è quella autosomica dominante che 
nella forma eterozigote ha una prevalenza di circa 1:500 individui, e nella 
forma omozigote ha una prevalenza di circa 1x106 individui. La malattia 
nella forma omozigote è caratterizzata da un fenotipo clinico con 
manifestazioni cliniche più severe che compaiono già in età pediatrica. 
Le mutazioni nel gene codificante per il recettore delle LDL (LDL-R) sono la 
causa più frequente, infatti, sono responsabili di circa 80% dei casi dell’FH. 
Un secondo gene coinvolto è l’APOB che codifica per l’apolipoproteina B, 
mutazioni in questo gene, sono identificate in circa 5-10% dei casi, infine un 
terzo gene coinvolto è PCSK9 che codifica per la Proproteina Convertasi 
Subtilisina/Kexina tipo9 responsabile di FH di tipo III in circa 1-2% dei casi. 
Lo studio dei tre geni responsabili della malattia è stato effettuato su 432 
pazienti, di cui 322 appartenenti a singole famiglie. Sono state identificate 
mutazioni in 214/322 soggetti (tasso di mutazione 66.5%). Dei 214 soggetti 
mutati, 204 (95.3%) presentavano mutazione nel gene LDLR, 6 (2.8%) 
mutazione in APOB and 4 (1.8%) mutazioni in PCSK9. Mediante le 
tecniche di sequenziamento diretto e Multiplex ligation-dependent probe 
amplification (MLPA) nel gene LDLR sono state identificate 58 differenti 
mutazioni, di cui circa il 50% rappresentano le mutazioni più comuni nelle 
regioni del Sud Italia questo dato è in accordo con quanto riportato in 
letteratura, la distribuzione delle mutazioni nel gene del recettore delle LDL 
tende a formare dei cluster tipici delle varie aree geografiche. Le mutazioni 
presenti solo nella nostra popolazione di soggetti FH sono 15 di cui 10 già 
descritte in due precedenti lavori e 5 riportate per la prima volta in questo 
studio di tesi. Sono state inoltre identificate 2 nuove mutazioni sia nel gene 
ApoB che nel gene PCSK9. Le nuove mutazioni sono state valutate 
mediante criteri indiretti quali: l'assenza delle mutazioni in 150 cromosomi 
provenienti da individui normocolesterolemici dello stesso gruppo etnico; la 
segregazione delle varianti con la patologia negli individui della stessa 
famiglia, la conservazione dei residui aminoacidici mutati nelle proteine 
omologhe di diverse specie. Le nuove mutazioni identificate nei geni LDLR, 
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APOB, PCSK9 sono state ricercate anche nel database che si avvale del 
sequenziamento degli esomi di 6500 individui, Exome Sequencing Project 
(ESP). Nessuna mutazione è stata ritrovata in EPS, inoltre, mediante 
l’utilizzo di software bioinformatici è stato possibile predire la causatività 
delle mutazioni mediante analisi in silico. Le analisi statistiche sono state 
effettuate con l’utilizzo di PASW versione 18.0 software (SPSS Inc.). Sono 
state osservate differenze statisticamente significative (p<0.0001) tra i 
gruppi di pazienti con e senza mutazione sia per i livelli di colesterolo-totale 
(TC) sia per i livelli di LDL-colesterolo (LDL-C). I pazienti con mutazione 
sono stati suddivisi in 4 gruppi in base al tipo di mutazione presente 
missenso, radicale, assenza di mutazione o presenza di due mutazioni 
(omozigoti o eterozigoti composti). L’analisi statistica dei dati biochimici 
correlati al tipo di mutazione, ha evidenziato come i livelli lipidici 
aumentavano in modo significativo dai pazienti senza mutazione ai pazienti 
con una mutazione missenso a pazienti con una mutazione radicale fino a 
quelli con due mutazioni. Tale significatività è stata osservata sia nel 
confronto fra i singoli gruppi mediante l’uso della correzione del Bonferroni 
sia nel confronto di tutti i gruppi mediante il Test di Kruskal-Wallis.  
I criteri diagnostici per porre diagnosi clinica di FH sono stati sviluppati, a 
livello internazionale, dal MedPed Program negli Stati Uniti (Make Early 
Diagnosys, Prevent Early Dead), dal Simon Broome Register Group nel 
Regno Unito e dal Dutch Lipid Clinic Network in Olanda. 
Il criterio del MedPed Program è basato sulla valutazione della 
colesterolemia in rapporto all’età del soggetto e al grado di parentela con 
altri familiari nei quali è stata già diagnosticata la FH. In mancanza di dati 
dei familiari si adotta un livello di cut-off del colesterolo totale che tiene 
conto della distribuzione della colesterolemia nella popolazione generale. Il 
criterio stabilito dal Simon Broome Register Group tiene conto oltre che dei 
livelli di CT e LDL-C in relazione all’età del paziente, anche di altre 
manifestazioni cliniche della malattia (xantomi tendinei), dell’anamnesi 
familiare e della diagnosi molecolare. Il criterio diagnostico del Dutch Lipid 
Clinic Network (DCLN) attribuisce invece un punteggio compreso tra 1 e 8 
a ciascun parametro di rilievo clinico per la patologia e quindi considera la 
diagnosi “certa” se il punteggio totale è superiore ad 8, “probabile” se il 
punteggio totale è compreso tra 6 ed 8 e “possibile” se il punteggio totale è 
tra 3 e 5. Secondo questi criteri, l’identificazione di mutazioni permette 
l’assegnazione di 8 punti e consente di porre diagnosi certa di FH.  
Le linee guida del Consensus Statement of the European Atherosclerosis 
Society (EAS) sottolineano l’importanza dell’utilizzo dei criteri diagnostici 
riportati nei DCLN e nei Simon Broome perché dotati di una maggiore  
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accuratezza diagnostica. Pertanto i 322 pazienti inclusi nello studio sono 
stati classificati in gruppi secondo quanto riportato nei criteri diagnostici 
DCLN e nei Simon Broome. Sono state effettuate delle analisi statistiche di 
correlazione tra presenza/assenza di mutazione sia nei gruppi DCLN che 
nei gruppi Simon Broome. La frequenza di mutazione osservata aumentava 
con l’aumentare della gravità del fenotipo clinico con un più alto numero di 
pazienti mutati presenti nel gruppo di FH-definita secondo entrambi i criteri 
diagnostici. Inoltre è stata valutata la correlazione tra il profilo lipidico dei 
pazienti con e senza mutazione e la classificazione secondo i due criteri 
diagnostici. Anche in questo caso i livelli di TC e LDL-C aumentano 
gradualmente da pazienti senza mutazione a quelli classificati con una 
probabile/possibile-FH a quelli classificati con una definita-FH che 
presentano dei valori di LDL-C quasi raddoppiati rispetto ai pazienti senza 
mutazione. Per verificare quale dei due criteri diagnostici fosse più accurato 
nel classificare i pazienti oggetto di questo studio il DCLN score e il Simon 
Broome sono stati correlati. 
Mediante l’utilizzo del test del chi-quadrato si è evidenziato che i due criteri 
nel 68% dei casi sono sovrapponibili, mostrando una concordanza del 
20.8% nella classificazione di pazienti senza mutazione nel gruppo con FH 
improbabile, del 42.1% nei pazienti con una possibile-FH e un 5.1% di 
pazienti con definita-FH. Le discrepanze sono dovute alla presenza di un 
16.1% di pazienti classificati come probabile/possibile-FH secondo i DCLN, 
come no-FH secondo i Simon Broome; da sottolineare inoltre la presenza 
di due pazienti classificati come definita-FH per i DCLN e come no-FH 
secondo i Simon Broome. Entrambi i pazienti presentano mutazione nel 
gene LDLR; la differenza nella classificazione è dovuta ad una diversa 
valutazione delle manifestazioni cliniche e storia personale tra i due criteri: 
un paziente presenta l’arco corneale e l’altro paziente presenta una placca 
carotidea manifestazioni cliniche non valutate nei Simon Broome ma 
considerati nei DCLN. Alla presenza di arco corneale viene attribuito un 
punteggio di 4 e alla presenza di placca carotidea viene attribuito un 
punteggio di 2, questi punteggi associati ai punteggi relativi ai livelli di LDL-
C permettono di assegnare uno score maggiore di 8 consentendo di  porre 
diagnosi certa di FH per entrambi i pazienti. 
Inoltre, in collaborazione con il gruppo di ricerca del Prof. Humphries 
dell’University College London è stata valutata la presenza di una 
componente poligenica in un sottogruppo di 199 soggetti con e senza 
mutazione nei tre geni candidati. Studi recenti hanno evidenziato come 
dalla valutazione della clinica verso la presenza di mutazione si osservano 
casi in cui alcuni soggetti con mutazione non hanno una diagnosi clinica di 
FH oppure soggetti senza mutazione sono classificati come FH. In questo  
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gruppo l’assenza di mutazione può essere dovuta alla presenza di varianti 
in altri geni coinvolti nel pathway del metabolismo delle LDL ma non ancora 
identificati come associati alla malattia o alla presenza di una componente 
poligenica. In un recente studio Talmud et al hanno osservato come la 
presenza di 12 SNP riportati dalla Global Lipid Genetic Consortium (GLGC) 
in pazienti senza mutazione fossero direttamente associati ad alti livelli di 
LDL-C. I nostri risultati confermano quanto precedentemente riportato e 
mostrano che anche nella nostra popolazione il fenotipo di FH in pazienti 
senza mutazioni nei tre principali geni candidati potrebbe essere dovuto ad 
una componente poligenica dovuta alla presenza di SNP responsabili 
dell’aumento dei livelli di LDL-C. Questo contributo poligenico è stato 
osservato anche nei pazienti con mutazione. 
L’analisi è stata estesa ad un sottogruppo di pazienti pediatrici (n=99) di età 
tra compresa 10 e 4 anni. In tale popolazione è stata osservata una 
differenza statisticamente significative tra i vari tipi di mutazione (missenso, 
radicale, assenza di mutazione o presenza di mutazione) e il profilo lipidico. 
E’ stato osservato che i livelli di LDL-C aumentano considerevolmente tra il 
gruppo di pazienti aventi due mutazioni (13.1±0.8 mmol/l) rispetto al gruppo 
senza mutazioni (4.0±1.6mmol/l). 
In conclusione, i risultati di questo studio rappresentano un aggiornamento 
dello studio genetico della Ipercolesterolemia Familiare nella popolazione 
italiana costituita da pazienti provenienti prevalentemente da regioni del 
Sud Italia.  
Questi dati evidenziano un aumento del numero di mutazioni causative di 
FH e sottolineano l’importanza di un completo screening dei geni coinvolti 
nella patologia per identificare nuove mutazioni e per identificare soggetti 
portatori di due mutazioni. La correlazione tra tipo di mutazione e profilo 
lipidico sottolinea l’importanza dell’analisi genetica come uno strumento 
prognostico. La presenza di una considerevole percentuale di soggetti 
mutati nel gruppo no-FH sulla base dei Dutch Lipid Clinic Network (DCLN) 
score e Simon Broome criteria suggeriscono che l’analisi genetica è anche 
utile per confermare la diagnosi specialmente nei pazienti con un fenotipo 
incerto. 
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1. Introduction 
 
1.1 Familial Hypercholesterolemia 
 
Monogenic hypercholesterolemia is a lipid metabolism disorder 
characterized by an increase in cholesterol. Cholesterol plays an essential 
role in the normal function of nearly all cells and is required by all steroid-
producing cells. Cholesterol, like most steroids, is a lipophilic molecule that 
circulates in blood bound to binding proteins that increase steroid solubility. 
Cholesterol is package in lipoprotein complexes referred to as high-density 
lipoproteins (HDL), low-density lipoproteins (LDL), and very-low-density 
lipoproteins (VLDL).  
Monogenic hypercholesterolemia includes two genetic subtypes designated 
as Autosomal Dominant Hypercholesterolemia (ADH) and Autosomal 
Recessive Hypercholesterolemia (ARH) [1]. 
Familial Hypercholesterolemia (FH, OMIM # 143890) is a common genetic 
cause that is inherited in an autosomal dominant manner. FH can be 
caused by mutations in the low-density lipoprotein receptor gene (LDLR) or 
in its main ligand apolipoprotein B gene (ApoB-100) [2], or in the propotein 
convertase subtilin/kexin type 9 gene (PCSK9) an enzyme involved in 
LDLR degradation [3] or in the other still unidentified genes [4].  
Recently, several loci have been reported with linkage studies, however to 
date this has not led to the identification of a specific causal gene [5].  
A recessive form of hypercholesterolemia is caused by very rare mutations 
in the low density lipoprotein receptor adaptor protein 1(LDLRAP1) gene 
[6]. 
FH leads to premature coronary heart disease(CHD), namely myocardial 
infarction and angina pectoris, due to elevated plasma low-density 
lipoprotein cholesterol (LDL-C) levels and high levels of total cholesterol 
(TC) [7].  
The clinical hallmark of FH is cholesterol ester accumulation in tissues 
manifesting tendon xanthomata and xanthelasmas involving the skin and 
extremities as well as the ocular orbit and the cornea (arcus corneae). 
However, a clinical diagnosis of FH is often made in the absence of tendom 
xanthomata, which are not usually present before the fourth decade of life. 
Despite its strong genetic background, FH shows a great variability in 
phenotypic expression in terms of the lipid profile, frequency of xanthomas, 
and onset and severity of CHD.  
It is well documented in the literature that FH is associated with substantial 
excess mortality from coronary heart disease in young adults but may not 
be associated with a substantial excess mortality in older patients.  
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Men and women with FH between 20 and 39 years old have a 100-fold 
increased risk to develop premature CHD compared to the normal 
population. It is thus important to identify, as early as possible, individuals 
with FH to improve their prognosis by administration of appropriate 
therapeutic interventions and it is crucial to perform cascade screening to 
detect familiars with the illness, especially children, before the 
manifestations of clinical symptoms [8].  
About 1 in 500 individuals in a general population is affected, making it the 
most common monogenic form of hypercholesterolemia. Patients with 
homozygous alleles for defective LDLR are very rare, the frequency is 
about 1:106. The clinical phenotype is more severe for homozygotes than 
heterozygotes; these patients usually die of severe coronary artery plaque 
formation. FH patients are increased lifetime risk for cardiovascular disease 
(CVD) during adolescence and, if left untreated, clinical symptoms of CVD 
typically manifest in men in their fourth decade and in women in their fifth 
decade of life in heterozygous FH patients. Usually, heterozygous patients 
have LDL-C concentrations less than 5mmol/l, however, the range of LDL-
C concentrations (5-11mmol/l) in heterozygous patients overlaps with 
concentrations observed in polygenic hypercholesterolemia [9]. 
Homozygous FH is characterized by extremely high concentrations of TC 
(usually in the range 15-24mmol/l) and LDL-C about 15.89mmol/l [9]. 
Patients with homozygous FH may have two identical mutations (true 
homozygote) or compound heterozygote having different mutations on each 
LDLR allele. Mutations in both LDLR alleles that result in reduced uptake 
and clearance of LDL-C is the most common cause of homozygous. 
Homozygotes are classified into two major groups based on the amount of 
LDLR activity: patients with less than 2% of normal LDLR activity are 
classified as receptor negative and patients with 2 to 25% of normal LDLR 
activity as receptor-defective [10].  
Homozygous patients can experience serious cardiovascular events as 
early as childhood [11]. Children with FH, particularly the homozygous form, 
have a much higher risk for premature CHD. Evidence that 
hypercholesterolemia is associated with the atherosclerotic process from 
childhood and is accompanied by increased prevalence of cardiovascular 
risk factors, justifies the screening for dyslipidemia in children. Children are 
subject to fewer environmental influences in terms of their lipoprotein 
metabolism, and an unequivocal diagnosis of ADH is easier to establish 
[12] . As a consequence, identification of FH during childhood, at the time of 
the silent and reversible phase of the disease, seems to be of paramount 
importance. 
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1.2 Diagnostic criteria for FH 
 
Clinical criteria used to identify patients with FH include: high plasma levels 
of total and LDL cholesterol, family history of hypercholesterolemia 
especially in children, physical examination, and personal and family 
history.The clinical phenotype of FH patients is variable. Three groups have 
developed diagnostic tools for FH: The US MedPed Program (Make Early 
Diagnosis, Prevent Early Death), the Simon Broome Register Group in the 
United Kingdom, and the Dutch Lipid Clinic Network (DLCNC). The major 
difference between these systems is the use of different cut-offs for 
premature CHD.  
The first, is based on validated age and sex adjusted serum cholesterol cut-
off points (Table 1). Different cut-off points are provided for each category 
for four age groups. The sensitivity and specificity of using cholesterol 
levels for diagnosis varies with the population involved. The authors 
estimated the cut-off levels of total cholesterol required to achieve 98% 
specificity, and showed that those levels would provide 88% sensitivity for 
screening first degree relatives and 54% sensitivity for screening the 
general population [13] [14]. 
 
Table 1. US MedPed Program diagnostic criteria for familial 
hypercholesterolemia 
 
The DLCNC score is based on a family history of hypercholesterolemia, 
premature CHD, clinical features, LDL-C levels and DNA analysis. It uses a 
numeric score for each criterion, and classifies individuals as “definite”, 
“probable” or “possible” FH. A diagnosis is considered definite if the score is  
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greater than 8, considered probable if the score is between 6 and 8 points, 
and considered possible when the score is between 3 and 5 points.  
If the score is below 3 points not diagnosis is made (Table 2) [15, 16]. It is 
also recommended that secondary causes of hypercholesterolemia 
(hypothyroidism, nephrotic syndrome, diabetes and medications) be 
excluded. The DCLNC criteria use a scoring system that is effectively 
similar to the Simon Broome Register criteria. 
 
Table 2. Dutch Lipid Clinic Network diagnostic criteria for familial 
hypercholesterolemia 
 
 
The Simon Broome Register criteria, take into account that TC and LDL-C 
levels differ for adults and children (Table 3). The criteria also take account 
of evidence of dominant transmission and the age of onset of coronary 
disease in the kindred. Using this approach, cases are categorized as 
‘definite’ and ‘possible’. If a mutation has not been identified, the presence 
of tendon xanthomas is required for a definite diagnosis of FH in Simon 
Broome Register criteria, whereas in the Dutch scoring system the 
presence of xanthomas only increases the score [13, 17]. 
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Table 3. Simon Broome Familial Hypercholesterolemia Register diagnostic 
criteria for familial hypercholesterolemia 
 
 
However, in some cases tendon xanthomata with normal plasma 
cholesterol may be seen in sitosterolemia and cerebrotendinous 
xanthomatosis but these should be excluded with plasma phytosterol and 
DNA testing [18].  
Furthermore, the Simon Broome Register criteria consider a molecular 
diagnosis as evidence for definite FH, the DLCNC requires that at least one  
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other criterion be met in addition to molecular diagnosis. These are the 
main differences between the DLCNC scoring system and the Simon 
Broome Register criteria [14]. 
In children, the diagnosis of FH cannot be made using the DLCNC score 
because children do not develop the physical signs of FH. In children and 
adolescents, the diagnosis of FH will be made using age and sex adjusted 
LDL-C levels and, where a family mutation is known, by DNA testing 
[19].The current approach to screening children and adolescents with a 
fasting lipid profile remains a targeted approach based on a family history of 
early coronary heart disease or elevated cholesterol levels. The absence of 
a positive genetic test in the parents does not exclude FH in a child with 
high cholesterol levels [20]. Testing of children families known to have a 
clear diagnosis of FH should be screened before the age of 10 years [21]. 
FH may be suspected in children if they have an untreated fasting LDL-C 
level above 3.5mmol/l; however, secondary causes of hypercholesterolemia 
(nephrotic syndrome and hypothyroidism) should first be excluded [22].  
In children with heterozygous clinical signs such as xanthomas and corneal 
arcus are not pathognomonic because they appear later in life; however, if 
present, they are suggestive of homozygous FH. The National Institute for 
Health and Clinical Excellence (NICE) guidelines state that all patients with 
a clinical diagnosis of FH should be offered a DNA diagnostic test and 
referral for family cascade testing in order to identify relatives affected [17]. 
Since FH is an autosomal dominant disease, the probability is 50% for a 
child of parent with FH to inherit the disease. Indeed, the most effective 
strategy for diagnosing patients with FH is to screen close relatives of 
patients already diagnosed with FH. In families where the mutation has 
been identified, genetic testing should also be included in cascade 
screening [23]. 
Cascade screening should start with first–degree relatives and then be 
extended to second and third degree relatives. A systematic strategy for 
detecting index cases of FH is essential. The index case is the trigger for 
cascade screening, whereby new cases can be efficiently discovered. 
Potential index cases should be sought amongst patients aged less than 
60years with CVD presenting to coronary, stroke and vascular care units 
[24]. 
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1.3 Molecular basis of FH 
 
1.3.1 LDL receptor gene 
 
The human gene encoding the LDLR is situated on chromosome 19p13 
with 18 exons that span approximately 45kb. The human LDLR messenger 
RNA (mRNA) is 5.3kb in length and encodes a protein of 860 amino acids 
[25].  
The LDLR is a multifunctional cell-surface glycoprotein, comprising several 
structural domains, that mediates the specific binding and uptake by 
receptor-mediated endocytosis of lipoproteins containing either ApoB or 
ApoE [26]. The protein is synthesized in the rough endoplasmic reticulum 
(ER) as a precursor protein, followed by a maturation process during the 
transportation to the Golgi apparatus, including elongation of carbohydrate 
chains, removal of signal peptides (21 amino acid), and conformational 
change. The 160 kDa transmembrane receptor is present at the surface of 
most cell types and mediates the transport of LDL-C into cells, through 
receptor-mediated endocytosis, thus playing a pivotal role in cholesterol 
homeostasis [27]. 
The mature form of the LDL receptor protein contains 839 amino acid 
residues and five functional domains: the ligand-binding domain, the 
epidermal growth factor (EGF) precursor homology domain, the O-linked 
polysaccharide domain, and the cytoplasmic domain (Fig.1). Different 
domains of the LDLR are responsible for different steps during lipoprotein 
uptake. 
 
 
Figure 1. Correlation of exon organization with protein domains in the LDL 
receptor 
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The ligand-binding domain contains seven tandem repeats (LA repeats 1-
7), each repeat contains six cysteine residues that form three intra repeat 
disulphide bonds. The LDLR uses LA repeats 4 and 5 to bind to ApoE on 
chylomicrons, VLDL and LA repeats 3-7 to bind ApoB on LDL-C. 
The EGF precursor is 33% identical to a portion of the human epidermal 
growth factor. This domain is required for the acid-dependent dissociation 
of lipoproteins from the receptor in the endosome during receptor recycling. 
The O-linked polysaccharide domain is region building sugars. 
The cytoplasmic domain, the membrane-spanning domain that anchors the 
protein to the cell membrane. 
The mutations in the LDLR gene in FH patients have helped to delineate 
the crucial steps of receptor mediated endocytosis. Many different 
mutations have been identified, and their effect on the structure and 
function of the protein in cultured cells, has shown that mutations in 
different regions of the protein can have very different effects on receptor 
function. 
Sequence variations have been categorized into 5 different classes based 
on biophysical and functional characteristics (Fig.2) 
 
 
Figure 2. The figure iIllustrates the five different classes for defects of LDL 
receptor function 
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Class 1. mutations fail to produce immune-precipitable proteins, no 
detectable LDLR proteins. This is the most common class of mutant alleles, 
accounting for approximately half of the mutations so far analyzed. 
Class 2.mutations encode proteins that are blocked, either completely 
(Class2A) or partially (Class2B), in transport between the ER and Golgi 
apparatus, transport defective alleles. These mutant receptors do not 
appear on the surface of the cells. This is the second most frequent class of 
mutations. 
Class 3.mutations encode proteins that are synthesized and transported to 
the cell surface, but fail to bind LDL normally. Defective LDL binding. 
Class 4.mutations encode proteins that move to the cell surface and bind 
LDL normally, but are unable to cluster in clathrin-coated pits and thus do 
not internalize LDL. Internalization-defective alleles. 
Class 5.mutations encode receptors that bind and internalize ligand in 
coated pits, but fail to release the ligand at acidic pH in the endosome and 
fail to recycle to the cell surface. Recycling-defective receptors [28]. 
Mutations in the LDLR gene are the most frequent cause of ADH 
accounting for about 85 to 90% of FH cases [8]. 
More than 1200 different mutations have been described in the literature so 
far, but only 79% are recognized to be pathogenic (http://www.ucl.ac.uk/fh) 
[29].  
LDLR mutations include mainly single nucleotide changes, which alter the 
amino acid composition of the mature protein, affect the correct splicing of 
the transcript, or binding of key transcription factors, if located in the 
promoter region. Large deletions and insertions account for approximately 
5-6%of all FH genetic defects. 
Although LDLR defects are primarily identified by genetic methods, it is 
extremely important to demonstrate a deficiency in the LDLR function of FH 
suspect patients through functional studies. Receptor assays reported 
include measurement of radiolabeled-LDL or fluorescently-labeled LDL 
binding and/or uptake in skin fibroblasts [25] or leukocytes [30].  
The Epstein-Barr virus (EBV)- transformed B-lymphocytes show high LDLR 
levels and allow an unlimited supply of cells without being influenced by the 
patient’s diet and drug treatment [31]. The main problem of these functional 
assays was the bad separation between residual LDLR activity from FH 
patients and controls. The separation of different leukocyte populations 
obtains more accurate results [32]; the selection of viable lymphocytes by 
stimulation with a mitogen or by flowcytometry gating improves the 
discrimination between patients and controls although it does not allow 
complete discrimination of FH heterozygote patients from healthy controls  
[33].  
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In a recent work, Romano et al demonstrated the possibility to discriminate 
between FH patients carrying LDLR mutations and healthy controls by an 
improved functional assay based on the DiI-LDL uptake in ionomycin plus 
PMA-stimulated T-lymphocytes and they have also identified a cut-off value 
with high sensitivity and specificity [34]. Many mutations in the LDLR gene 
have been described in various countries around the world and disease 
incidence appears to be higher in certain nationalities and geographical 
areas with elevated cardiovascular risk [35]. The specific point of mutations, 
deletions, frameshifts, inheritance patterns and geographical distribution 
can be reviewed on line through the “Online Mendelian Inheritance in Man” 
web site (OMIM, Mckusick-Nathans Institute for Genetic Medicine, 
JohnsHopkinsUniversity (Baltimore, MD) and National Center for 
Biotecnology Information, National Library of Medicine (Bethesda, MD), 
2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). 
The distribution of causative FH mutations in Europe varies between 
countries; some populations, such as French and Italian, demonstrate 
considerable heterogeneity, while others involve a narrow range of 
causative mutations and are relatively homogenous [35]. The mutation 
spectrum in Italy consists of over 80 mutations including large 
rearrangements, missense and nonsense mutations. Some of these 
mutations are specific to certain regions of Italy; for example, the 
p.Gly549Asp mutation is found predominantly in the southern regions of 
Italy [36]. Moreover, it seems that some of these genetic changes are 
present in areas of relatively high incidence (FH-clusters) and may 
represent a “founder effect”. A founder effect occurs when a subpopulation 
is formed through the immigration of a small number of "founder" subjects, 
followed by population expansion. If, by chance, some of the founders had 
FH, then genetic drift could lead to a high proportion of affected subjects 
who share specific mutations introduced by the founders. 
The high number of different FH mutations makes genetic testing labour-
intensive and costly, which has encouraged the development of novel 
assays and techniques such as next-generation sequencing (NGS) for 
diseases like FH [37]. 
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1.3.2 Apolipoprotein-B gene 
 
In humans, most of plasma cholesterol is transported in LDL. This 
lipoprotein consists of a central core composed of apolar neutral lipids 
(triglycerides and cholesteryl esters) and an outer shell of phospholipids, 
unsterilized cholesterol, and a single ApoB molecule its protein component 
(Fig.3) [38]. ApoB plays a central role in intracellular assembly and 
secretion of triglyceride-rich (TG-rich) lipoproteins and is a ligand for LDLR 
[39]. 
 
 
Figure 3. Schematic representation of a generic lipoprotein particle. 
 
The ApoB gene is 43kb in length, contains 28 introns and 29 exons, and is 
located on the short arm of chromosome 2 and mRNA is 14.5kb in length 
and codes for a mature protein of 4536 amino acids. The protein has four 
well-recognized functional actives. First, it is required for the synthesis, 
assembly, and secretion of hepatic TG-rich lipoproteins. Second, it binds to 
lipids and is a structural component of VLDL and LDL. Third, it binds to 
heparin and various proteoglycans found in the arterial wall. Finally, ApoB 
mediates the uptake of LDL particles by liver and peripheral tissue via a 
specific interaction with the LDLR [2].  
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ApoB is the ligand for the LDLR and sole apolipoprotein on the surface of 
LDL; it is wrapped around the LDL particle as a belt and there are some 
critical residues that are crucial for the ApoB-LDLR affinity within this 
configuration [40]. The LDLR-binding domain was localized to the region 
between residues 3386 and 3396, it was shown that alterations involving 
this amino acid destabilize important clusters for the APOB conformation, 
altering in this way its affinity for the LDLR; additionally, regions between 
amino acid 3174 and 3184 and also 4181 and 4540 were proved to be 
important for the correct folding of the carboxyl terminus of APOB 
necessary for binding to the LDLR [41].  
Goldestein was the first to indicate that a defect in apoB-100 can lead to a 
phenotype similar to FH by observation of decreased fractional catabolic 
rates of autologous LDL compared with homologous LDL in five subjects 
[42]. APOB mutations causing FH are estimated to occur in 1:300 to 1:700 
people in several Caucasian populations in Europe [35]. The penetrance of 
APOB mutations has been shown to be <100% and patients with APOB 
mutations usually have a less severe phenotype than FH patients due to 
LDLR mutations [43]. In contrast to the large number of variations identified 
in the LDLR gene, only a few variations have been characterized in the 
ApoB gene. The most frequent mutation is p.Arg3500Gln that causes 
defective binding of the LDLR with is ApoB ligand, leading to decreased 
clearance of circulating LDL. The Arg3500Gln mutation in APOB is the 
most common cause of hypercholesterolemia due to an APOB mutation, 
accounting for 5 to 10% of FH cases in Northern European populations 
(rare in other populations) [8]. 
The binding affinities of p.Arg3500Gln to the LDL receptor is reduced to 
30% [44]. Interestingly, this mutation is not located at the LDLR-binding 
site. Instead, an Arg3500-Try4369 interaction is necessary to ensure the 
proper conformational shape of the ApoB protein, and mutations in these 
key amino acid result in improper protein folding and reduced receptor 
binding [41]. However, a large number of ApoB gene mutations truncating 
ApoB have been reported to be cause of Familial Hypobetalipoproteinemia 
(FHBL) [45]. Missense mutations of the APOB gene can also be the cause 
of FHBL and are associated with a decreased secretion of the mutant 
APOB because of an increased binding to microsomal triglyceride transfer 
protein[46]. Mutations in APOB that reduce translation or secretion, or 
enhance the catabolism of APOB are associated with reduced plasma LDL-
C levels and reduce risk of coronary disease [47]. In line with this, patients 
with extremely low levels of APOB (< 5th percentile) due to FHBL seem to 
be protected against CVD [48]. Based on these observations APOB is 
conceptually an attractive target to reduce CVD risk. 
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1.3.3 Proprotein convertase subtilisin/kexin type 9 gene 
 
PCSK9 is the ninth member of the Proprotein Convertase (PC) family that 
has profound effects on plasma LDL-C levels through its ability to mediate 
LDL receptor protein degradation. The PCSK9 gene is localized on 
chromosome 1p32.3. This gene is about 22kb and comprises 12 exons 
encoding a 692 amino acid glycoprotein. This convertase is highly 
expressed in the liver, small intestine, and brain, kidney and is present in 
human plasma [49].   
PCSK9 is synthesized as a 74 kDa soluble zymogen (proPCSK9) that 
undergoes autocatalytic cleavage at position 152 in the endoplasmic 
reticulum to release the propeptide (14 kDa) from the N-terminus resulting 
in a mature enzyme of about 60 kDa [50] (Fig.4). The cleavage of the pro-
domain is strictly required for PCSK9 maturation and activation. 
 
Figure 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) structure 
The protein domains that comprise PCSK9 are a pro-peptide or inhibitory 
pro-domain, the subtilisin-like catalytic domain, and a cysteine-rich, unique, 
C terminal domain amino acids[51](Piper DE et al Structure 2007). PCSK9 
complexes with the LDLR and is taken up together in clathrin coated pits by 
hepatocytes. The region within the LDLR that is bound by catalytic domain 
of PCSK9 corresponds to EGF-A located within the EGF receptor precursor 
homology domain [52].  
PCSK9 binding to this site is absolutely required for LDLR degradation, 
even though other regions of the LDLR that do not interact with PCSK9 are 
important for PCSK9-mediated LDLR degradation [53].  
A recent study has demonstrated that a soluble EGF-A peptide acts as 
decoy and inhibits the binding of PCSK9 to LDLR thus providing evidence  
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for the crucial role of the EGF-A domain in the PCSK9 regulatory pathway 
[54]. Secreted PCSK9 in the media of cultured cells or in human plasma 
binds to the EGF-A of the cell-surface LDLR. PCSK9 bound to the LDLR is 
subsequently internalized by endocytosis, the PCSK9-LDLR complex is 
located in the sorting endosomes. In contrast to the binding of LDL to the 
LDLR, PCSK9-LDL receptor affinity is increased at an acidic endosome pH 
and failure to release PCSK9 prevents receptor recycling and directs the 
PCSK9-LDLR complex to the lysosome, where degradation of the LDLR 
occurs.PCSK9 also targets the LDLR within the cell independently of 
endocytosis. In fact, adenovirally mediated PCSK9 overexpression 
accelerates the degradation of the LDLR in a post endoplasmic reticulum 
compartment [55] (Fig.5). 
PCSK9 thus regulates the number of LDLR on the cell surface of 
hepatocytes. Findings also demonstrate that the LDL receptor plays a 
critical role in facilitating the trafficking of PCSK9 from the endoplasmic 
reticulum to downstream sites in the secretory and endocytic pathways.  
 
 
Figure 5. PCSK9-mediated degradation of the LDLR. A complex of LDL-C, 
LDLR and PCSK9 is internalized and undergoes lysosomal degradation. 
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Mutations in PCSK9 have been found to decrease or increase the ability of 
PCSK9 to degrade the LDLR. Loss-of-function mutations which reduce the 
ability of the mutant PCSK9 to degrade the LDLR, result in a higher number 
of cell-surface LDLR and reduced levels of LCL-C in plasma [56]. 
Conversely, gain-of-function mutations which increase the ability of the 
mutant PCSK9 to degrade the LDLR, result in a lower number of cell-
surface LDLR and increased levels of LDL-C in plasma [56]. Thus, 
mutations in PCSK9 would be associated with the development of 
hypercholesterolemia or hypocholesterolemia, respectively. Gain-of-
function mutations in PCSK9 cause fewer than 5% of hypercholesterolemia 
cases in most studies. 
Phenotypic variations in patients heterozygous for a mutation in the PCSK9 
gene has not yet been evaluated. The clinical comparison of PCSK9 
mutation carriers to subjects with mutations in the LDLR or ApoB is difficult 
to estimate to date as most PCSK9 mutation carriers were identified in a 
sample selected for clinical diagnosis of FH [3]. After the initial report that 
gain-of-function mutations in the PCSK9 gene cause hypercholesterolemia, 
PCSK9 has gained large interest as a target for lipid lowering.  
PCSK9 has been shown to be a pivotal regulator of LDL-C metabolism 
thanks to its role in lysosomal degradation of LDL receptor within 
hepatocytes. The notion that loss-of-function PCSK9 mutations confer an 
80% CVD risk reduction has further substantiated the role of PCSK9 as a 
potential target for therapy [57]. 
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1.4 Autosomal Recessive hypercholesterolemia (ARH) and LDLRAP1 gene 
 
In 1973, Khachadurian and Uthman first described what is now termed 
Autosomal Recessive hypercholesterolemia (ARH) [58]. 
ARH is caused by mutations in the LDL receptor adaptor protein 1 gene, 
which encodes an adaptor protein required for normal LDL receptor-
mediated endocytosis in hepatocytes and governs the clustering of the 
LDLR into clathrin-coated pits [58]. 
The gene spans about 25 kb and has nine exons and eight introns. The 
predicted amino acid sequence contains a 170–amino acid motif that 
shares considerable sequence similarity with the phosphotyrosine binding 
(PTB) domains of many adaptor proteins. PTB domain (residues 40-180) 
binds the consensus sequence NPXY, which is present in the cytoplasmic 
domains of several cell-surface receptors, including the epidermal growth 
factor receptor, the insulin receptor, nerve growth factor receptor (TrkA) and 
the LDLR  [59, 60]. 
ARH is a rare disorder in most countries with the exception of the island of 
Sardinia(Italy), where the disease is not uncommon (frequency1:40,000 for 
homozygotes and compound heterozygotes), probably as the result of a 
founder effect and inbreeding [61]. ARH has been considered a phenocopy 
of homozygous FH due to LDLR mutations. Plasma levels of LDL-C in ARH 
patients tend to be intermediate between those in FH heterozygotes and 
those in FH homozygotes. However, the prevalence for developing early 
onset CHD is lower compared to FH patients with strong homozygous 
LDLR mutations [62] but patients with ARH often have large, bulky 
xanthomas [63].  
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1.5 Polygenic basis for hypercholesterolemia 
 
Recently, the European Atherosclerosis Society (EAS) have also released 
guidelines for the management of dyslipidaemias. They reported that some 
10%-40%, depending on referral criteria, of patients with a clinical diagnosis 
will not have a detectable causal mutation; rather, they have a clinical 
diagnosis of FH but not a mutation diagnosis. There may therefore be yet 
genes implicated in this disease; alternatively, these individuals may 
present a polygenic basis for their LDL cholesterol elevation without 
contributions from any of the classical FH genes (Fig.6). 
 
 
Figure 6. Overlap of clinical and mutation diagnosis of heterozygous FH 
 
Recent genome-wide association studies (GWASs) have localized common 
DNA sequence variants that contribute to many human phenotypes. The 
success of this approach has been particularly notable for blood lipoprotein 
levels. 
Small-scale studies have also shown that some individuals carry multiple 
mutations in different genes, with established roles in lipid metabolism in 
families with apparent Mendelian forms of dyslipidemia [64]. 
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Since the beginning of large-scale GWAS in 2008 until today, the number of 
candidate genes associated with plasma lipid phenotypes has steadily 
increased [65]. In fact, the Global Lipid Genetic Consortium (GLGC) meta-
analysis of GWASs studies identified several loci where common variants 
affect LDL-C concentration, and results of another study showed that a 
proportion of individuals carrying several LDL-raising single nucleotide 
polymorphisms (SNPs) have elevated levels of LDL-C [66]. 
A recent study in English and Belgian FH patients [67], has reported that in 
a proportion of patients where no mutation can be found in these genes, the 
disease could be polygenic, due to SNPs strongly associated with LDL-C. 
However, a proportion of all clinically diagnosed cases of FH could be 
polygenic, due to the inheritance of a greater than average number of 
common LDL-C raising alleles leading to an increase in LDL-C above the 
diagnostic cutoff.  
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1.6 Treatment for FH 
 
The aim of treatment of FH patients is the reduction of plasma LDL-C levels 
to decrease the risk of premature CVD. All subjects with FH and their 
families should undergo intensive education targeting lifestyle 
management, including a healthy diet, exercise, weight control, blood 
pressure control, and smoking cessation [68].  
The most popular and commonly prescribed cholesterol-lowering agents 
are statins, the 3β-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCR) inhibitors. HMGCR catalyzes the rate limiting step in the 
biosynthesis of sterols, cholesterol and isoprenoids. The statin class of 
cholesterol-lowering drugs have been used for decades to successfully 
lower plasma cholesterol concentrations and cardiovascular risk.  
Statin drug therapy significantly reduces the morbidity and mortality from 
premature CHD in heterozygous FH patients lowering cholesterol and 
stimulating the production of the LDLR in livers cells [9]. Clinical endpoint 
trials of lipid-lowering drug therapy with statins have demonstrated their 
effectiveness in the primary and secondary prevention of coronary heart 
disease risk, especially in the highest risk groups [69]. 
Although there are no randomized clinical trials designed specifically for  
patients with familial hypercholesterolemia, observational studies strongly 
suggest that statins reduce disease risk in FH individuals [70]. Although in 
some heterozygous FH and polygenic hypercholesterolemia individuals, 
LDL-C treatment goals cannot be reached with the maximum available or 
tolerated dose of statin, these patients might be administered a statin 
therapy in combination with other lipid-lowering therapies including 
ezetimibe and resins [71].  
Patients with homozygous FH generally respond to a lesser degree 
compared with heterozygous FH individuals. In patients with homozygous 
FH who are inadequately controlled on statins alone, the current practice is 
to perform LDL apheresis at weekly intervals to achieve the lowest possible 
LDL cholesterol levels [72]. It is generally agreed that targets for LDL-C 
treatment in children need not be as low as those of adults.  
Like in adults good evidence for an absolute or relative target does not exist 
in children. Numerous clinical trials of the safety and efficacy of statins for 
lowering LDL cholesterol have been conducted in children and adolescents 
with severe dyslipidemia. Current pediatric guidelines recommend to start 
the statin therapy at the age of 8 years or older. The drug therapy in 
children aged under eight is only recommended in cases of marked 
elevation of LDL-C usually found in homozygous forms of FH [73] [22]. 
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1.7 New treatments for FH 
 
Current therapeutic approaches with lipid-lowering agents, such as statins, 
fail to protect more than half of patients from cardiovascular events. High 
statin doses are often associated with an increased frequency of adverse 
effects. Therefore, there is a need for additional and alternative treatment 
options. There are several promising novel therapeutic approaches for the 
treatment of dyslipidaemia and atherosclerosis, which are expected to be of 
great benefit for patients at risk of cardiovascular disease. 
Among the emerging therapeutic options, the most advanced one is the use 
of antisense oligonucleotides (ASOs) to ApoB-100 mRNA.  
Mipomersen or ISIS 301012 is a second-generation antisense 
oligonucleotide consisting of 20 base pairs, complementary to the coding 
region for human ApoB-100 mRNA [9]. Mipomersen has been shown to 
reduce serum LDL-C in patients with homozygous, heterozygous FH and 
severe hypercholesterolemia [74]. Mipomersen can induce hepatic 
staetosis in 16% of patients and elevations in plasma amino transferases in 
8% of patients [75]. Microsomal Triglyceride transfer protein (MTP) plays an 
important role in the formation of ApoB. Consequently, MTP inhibition could 
lead to reductions in the secretion of atherogenic lipoproteins from the liver 
and also reduce the assembly and secretion of chylomicrons in the intestine 
[76]. However, in the US Mipomersen (has orphan drug status and, 
because of the risk of hepatotoxicity), can only be prescribed through a 
Risk Evaluation Mitigation Strategy (REMS) programme as it is an orphan 
drug with a risk of hepatotoxicity.  
The target for a new therapy is Microsomal triglyceride transfer (MTP) 
which localizes to the endoplasmatic reticulum of hepatocytes and 
enterocytes. It transfers triglycerides to the nascent APOB to produce VLDL 
and chylomicrons. Lomitapide is an oral MTP inhibitor that is intended to 
treat homozygotes. However, pharmacological inhibition of MTP has 
resulted in significant increases in hepatic steatosis [11]. 
Another possible target of therapy is PCSK9. A number of strategies to 
specifically lower PCSK9 activity are currently in different stages of 
development and testing. The most advanced strategy is the use of small 
interfering RNAs and monoclonal antibodies against PCSK9: a monoclonal 
antibody can inhibit PCSK9 binding to LDLR attenuating PCSK9-mediated 
reduction in LDLR protein concentration [77].  
The inhibition of PCSK9 is the most attractive new approach to reducing 
atherogenic lipoproteins and enhancing the efficacy of statins. Current data 
suggest that these drugs will provide an effective therapeutic option for 
LDL-C reduction and, if proven safe in phase III trials, they will be equally  
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important to LDL-C control [78]. However, Mipomersen and Lomitapide are 
approved specially for homozygotes FH.PCSK9 inhibitors are not yet 
licensed for use in FH, but clinical trial data suggest that they may have 
broad applications for patients with heterozygous FH who do not respond to 
or who are intolerant of statins [79]. 
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2. Aims 
 
Familial Hypercholesterolemia is an  inherited genetic defect resulting in 
elevated serum LDL-cholesterol concentrations. 
The clinical phenotype of FH is known to be due to mutations in three 
genes encoding proteins involved in the clearance of LDL-C from plasma, 
LDLR, APOB and PCSK9. 
Genetic screening for FH is generally useful to confirm the diagnosis in FH 
patients and it  is essential if the clinical diagnosis is uncertain. The  
Identification of a causative mutation may provide an additional motivation 
to implement an appropriate treatment for some patients. 
The aims of this study are: 
To identify new and known  mutations in the three candidate genes, in an 
attempt to determine to what extent the type of genetic defects is an 
important determinant of the FH phenotype. 
To  assess the frequency and spectrum of mutations recognised causing  
FH among patients attending the different Italian lipid clinics. 
To investigate genotype-phenotype correlations in FH carrying different 
mutations of the LDL-R gene in order to show how the type of the LDLR 
mutation influences the lipid profile. 
To  evaluate which of diagnostic criteria DCLN or Simon Broome is more 
accurate to detect patients with mutations in our population. 
In addition, our aim is also to identify the  presence of a likely polygenic 
cause due to the inheritance of LDL-C-raising SNPs which increases LDL-C 
concentration in a proportion of patients with and without mutations in 
LDLR, APOB, PCSK9. 
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3. Materials and Methods 
 
3.1 Studied population 
 
This study includes a total of 432 patients with the clinical diagnosis of FH, 
of which 322 probands were apparently unrelated. The cohort of patients 
were enrolled at the different Italian lipid clinics. The FH diagnosis was 
based on personal and family history, physical examination, and untreated 
plasma low-density LDL-C level >4.9mmol/l. Patients with 
hypercholesterolemia due to secondary causes including diabetes, 
hypothyroidism and nephrotic syndrome were excluded. Premature 
coronary artery disease and risk factors for heart disease, including 
diabetes mellitus, hypertension, family history of premature coronary artery 
disease in first-degree relatives, and smoking habits, were recorded. Family 
members with identified mutations were also invited to participate in this 
investigation. The cohort consisted of 214 FH-mutation positive (FH-M+) 
and 108 FH-mutation negative (FH-M-) patients. The control group was 
made of 150 chromosomes of normolipidemic subjects with no history of 
FH or premature CHD. All novel variations found were searched in Exome 
Sequencing project (ESP). The study protocol was approved by the 
institutional review board of the hospital, and informed consent was 
obtained from each patient or, in the case of children, from their parents. 
 
3.2 Biochemical analysis 
 
Biochemical markers were measured on serum after an overnight fast. 
Total cholesterol, triglyceride and glucose levels were evaluated by 
standard methods using an automated analyser (Modular P3, Roche). The 
HDL cholesterol concentrations were measured using a homogeneous 
enzymatic colorimetric assay and the automated Modular P3 analyzer 
(Roche). The LDL cholesterol concentrations were calculated according to 
the Friedewald formula (Friedewald WT, Levy RI, Fredrickson DS. 
Estimation of the concentration of low-density lipoprotein cholesterol in 
plasma, without use of the preparative ultracentrifuge. Clin Chem 
1972;18:499-502) or measured using a homogeneous enzymatic 
colorimetric assay if triglycerides levels are greater than 4.52mmol/l. LDL 
particles separation was performed by Lipoprint System (Quantimetrix Inc.).  
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3.3 Mutation screening 
 
Genomic DNA was extracted from whole blood using a Nucleon BACC 
Genomic DNA Extraction Kits (GE Healthcare Life Sciences).  
A screening of the genes associated with the disease was performed to 
confirm the diagnosis of FH. The promoter, 18 coding exons, and flanking 
intron regions of the LDLR gene were amplified by polymerase chain 
reaction (PCR) using True Allelic Premix (Applied Biosystems) according to 
the manufacturer’s instructions.  
PCSK9 mutation screening was performed through amplification of the 12 
exons with flanking intron sequences, whereas APOB screening included 
the extended binding region of the APOB gene using True Allelic Premix 
(Applied Biosystems) according to the manufacturer’s instructions.  
The amplicons were amplified in 30 µL containing 250 ng DNA and 15 pmol 
of each primer.  
Direct bidirectional sequencing analysis of purified PCR product was 
carried out using the BigDye terminator cycle sequencing ready reaction kit 
and an ABI Prism 3100 DNA genetic analyzer (Applied Biosystems). 
CodonCode Aligner version 4.1. software was used for sequence analysis. 
When new mutation was detected, another sequencing reaction was 
performed both on genomic DNA from the relative and from a new PCR 
product from the proband. The amino acid numbers of the LDLR, APOB 
and PCSK9 are in agreement with the international nomenclature which 
starts from the initiating methionine and includes the amino acids of the 
signal peptide (http://www.hgvs.org/mutnomen/).  
The causative role of the new mutation was verified according to the 
following criteria: 1. the absence of the mutation in 150 chromosomes from 
normocholesterolemic individuals; 2. the conservation of the substituted 
amino acid residue across homologous proteins by BLASTP; 3. the 
segregation of the variant with the FH phenotype in the family.  
 
3.4 In silico analysis 
 
The potential clinical impact of new variations in LDLR, APOB and PCSK9 
genes was assessed using algorithms on pathogenicity predictive websites: 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), SIFT Human Protein 
(http://sift.jcvi.org), Mutation Taster (http://www.mutationtaster.org) and 
PMut (http://mmb.pcb.ub.es/) 
The effect of intronic variants on splicing was performed using NetGene2 
(http://www.cbs.dtudk/services/NetGene2), Human Splicing Finder 
(htt://umd.be/HSF/HSF.html) and Automated Splice Site Analysis  
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(https://splice.uwo.ca). These programs give predictive scores for splice 
acceptor and donor sequences for wild type and variant sequences. 
Alterations in the scores between wild type and variations allow an 
assessment to be made regarding whether or not normal exon splicing will 
be affected. 
 
3.5 Multiplex Ligation-dependent Probe Amplification (MLPA)  
 
MLPA is a rapid, high-throughput technique for copy number quantification 
and methylation status analysis of genomic sequences. 
The SALSA P062-B LDLR MLPA kit was obtained from MRC-Holland 
(Amsterdam, The Netherlands). The LDLR MLPA kit contained 37 sets of 
probes, 19 of which were LDLR specific and the others were control 
standards. Reactions were carried out in 200-µl tubes in a model 9700 
thermocycler (PE-Applied Biosystems, Foster City, California). 
Each MLPA probe consists of a pair of oligonucleotides, one synthetic and 
one M13 derived. Each of the two oligonucleotides contains one of the two 
sequences recognized by the polymerase chain reaction (PCR) primers. 
One probe oligonucleotide contains a non-hybridized stuffer sequence of 
variable length (19–370 nucleotides). The two parts of each probe hybridize 
to adjacent target sequences and are ligated by a thermostable ligase. 
Upon ligation, a single molecule is formed that can be amplified during 
PCR. Following PCR, amplicons are separated and quantified by capillary 
electrophoresis.  
Peaks on each electropherogram were normalized by expressing their 
heights a fraction of the total height of all control peaks. 
Each probe in an MLPA probe set has a unique length and can therefore be 
easily identified. The procedure was performed according to the 
manufacturer’s instructions (www.mrc-holland.com). To obtain gene dosage 
quotients, the results were compared with three control samples analysed 
at the same time using the Coffalyser data analysis tool (MRC-Holland). 
 
3.6 Global Lipids Genetic Consortium gene score calculation 
 
The GLGC reported SNPs that were significantly associated with LDL-C, 
with a p-value cut-off of less than 5×10 [66]. For the purpose of the gene 
score calculation only the lead SNP from each locus was selected and if a 
SNP was associated with more than one lipid fraction it was only used in 
this score calculation if LDL-C was the lead trait (most strongly associated 
trait) for the SNP.  
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The TaqMan assay was performed for 12 common SNPs, in 11 genes (two 
in APOE) that the Global Lipid Genetic Consortium (GLGC) reported as 
significantly associated with LDL-C. The possibility of polygenic 
hypercholesterolemia was assessed in 199 patients who had a clinical 
diagnosis of FH with or without an identified familial hypercholesterolemia-
causing mutation. Gene scores of a randomly selected samples from the 
UK Whitehall II (WHII) study (n=3020) were used as a healthy control 
comparison group.  
For each individual, the LDL-C-specific gene scores were calculated using 
the weighted sum of the risk allele (Table 4). Individuals with gene score 
above 1.16, which was the top decile cutoff for the WHII subjects, were 
considered to have polygenic hypercholesterolemia.  
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Table 4. Global Lipid Genetic Consortium 12-SNP LDL-C gene score 
calculation 
 
Chromosome 
number Gene 
Minor 
allele 
Common 
allele 
GLGC 
weight 
for score 
calculation 
rs2479409 1 PCSK9 G* A 0·052 
rs629301 1 CELSR2 G T* 0·15 
rs1367117 2 APOB A* G 0·10 
rs4299376 2 ABCG8 G* T 0·071 
rs1564348 6 SLC22A1 C T* 0·014 
rs1800562 6 HFE A G* 0·057 
rs3757354 6 MYLIP T C* 0·037 
rs11220462 11 ST3GAL4 A* G 0·050 
rs8017377 14 NYNRIN A* G 0·029 
rs6511720 19 LDLR T G* 0·18 
rs429358 19 APOE C T ·· 
rs7412 19 APOE T C ·· 
ε2ε2 19 APOE ·· ·· −0·9 
ε2ε3 19 APOE ·· ·· −0·4 
ε2ε4 19 APOE ·· ·· 0·2 
ε3ε3 19 APOE ·· ·· 0 
ε3ε4 19 APOE ·· ·· 0·1 
ε4ε4 19 APOE ·· ·· 0·2 
 
* Risk alleles (LDL-raising). 
 
3.7 SNP Genotyping Analysis Using TaqMan Assays 
 
TaqMan 5'-nuclease assay chemistry provides a fast and simple way to get 
single nucleotide polymorphism (SNP) genotyping results TaqMan assays 
contain two specific primers targeting the region flanking the SNP site and 
two TaqMan fluorescent probes with a Minor Groove Binder (MGB). These 
TaqMan probe and primer sets (assays) uniquely align with the genome to 
provide unmatched specificity for the allele of interest. 
Each probe is labeled with a different fluorophore (VIC or 6-FAM). These 
reporters are attached covalently to the 5' end of the two probes. Near the 3 
'end, there is a non-fluorescent quencher (NFQ) that prevents liberation of 
the reporter fluorescence if the probe is not degraded. The MGB serves to 
stabilize the double-stranded structure formed between the target and the  
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probe. During the PCR reaction, probes that hybridize specifically to DNA 
fragments are destroyed and the fluorescence of corresponding fluorophore 
is liberated. The oligonucleotide is designed such that there are 
complementary regions at each end and a probe sequence located in 
between. This design allows the probe to take on a hairpin, or stem-loop, 
structure in its natural, isolated state. Because of the stem-loop structure of 
the probe, the fluorophore is in close proximity to the quencher, thus 
preventing the molecule from emitting any fluorescence. The molecule is 
also engineered such that only the probe sequence is complementary to 
the genomic DNA that will be used in the assay [80]. 
If the probe sequence of the molecular beacon encounters its target 
genomic DNA during  
the assay, it will anneal and hybridize. Because of the length of the probe 
sequence, the hairpin segment of the probe will be denatured in favour of 
forming a longer, more stable probe-target hybrid. This conformational 
change permits the fluorophore and quencher to be free of their tight 
proximity due to the hairpin association, allowing the molecule to fluoresce. 
If on the other hand, the probe sequence encounters a target sequence 
with as little as one non-complementary nucleotide, the molecular beacon 
will preferentially stay in its natural hairpin state and no fluorescence will be 
observed, as the fluorophore remains quenched. 
The unique design of these molecular beacons allows for a simple 
diagnostic assay to identify SNPs at a given location. If a molecular beacon 
is designed to match a wild-type allele and another to match a mutant of the 
allele, the two can be used to identify the genotype of an individual. If only 
the first probe’s fluorophore wavelength is detected during the assay then 
the individual is homozygous to the wild type. If only the second probe’s 
wavelength is detected then the individual is homozygous to the mutant 
allele. Finally, if both wavelengths are detected, then both molecular 
beacons must be hybridizing to their complements and thus the individual 
must contain both alleles and be heterozygous. 
Reactions were carried out in 384 plate (384 Well Clear Optical Reaction 
Plate), prepared with Biomek 2000 Workstation (Beckman), in ABI PRISM 
7900 HT Real-time PCR system. 
After PCR amplification and end-point fluorescence detection, genotypes 
are scored using SDS 2.3 (Sequence Detection System, Applied 
Biosystems) analysis software, which displays fluorescence data in a X-Y 
plot format for easy clustering and scoring. 
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3.8 Statistical analysis 
 
Continuous variables were expressed as a mean ± SD (parametric 
distributions) or median value and 25-75 percentile (non-parametric 
distributions) and categorical data as the absolute number and percentage. 
Kolmogorov-Smirnov test was performed to assess the hypothesis of a 
normal distribution of variables. Differences between groups were assessed 
by T-test, non-parametric Mann-Whitney test and chi-square test, as 
appropriate. Genotype and allele frequencies were calculated by allele 
counting and departure from Hardy-Weinberg expectation was evaluated by 
chi-square analysis (all SNPs were in equilibrium). Analysis of variance 
(ANOVA) was used to analyze the differences between group means and 
their associated procedure. The Kruskal–Wallis one-way analysis of 
variance by ranks was used in multiple test when the variable was non-
parametric distribution. To correct the multiple testing was used by 
Bonferroni test.  
To test the type of association, dominant and recessive models were 
constructed for the rare allele of each polymorphism and univariate odds 
ratio (OR) with 95% Confidence Interval (CI) were calculated.  
The linear regression was performed of observed baseline LDL-C 
concentrations with the weighted LDL-C gene scores. The risk ratio was 
calculated of having a measured LDL-C concentration of higher than 4.9 
mmol/l by deciles of the GLGC weighted score in WHII controls.  
Statistical analysis was performed with PASW version 18.0 software (SPSS 
Inc.).  
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4. Results 
 
4.1 Patients characteristics  
 
In the group of 432 patients, 322 unrelated (age 33 ± 18) were screened for 
FH mutations in three candidate genes, LDLR, APOB, PCSK9. The clinical 
characteristics of the subjects enrolled are reported in Table 5. There was 
no significant difference in the male/female ratio between the groups of FH-
M+ and FH-M- but the age was significantly different between the two 
groups (p=0.001). The patients bearing mutations were younger than those 
without any mutation. All lipid parameters showed non-parametric 
distributions, the data was reported as median and 25-75 percentiles.  
The median total cholesterol (8.3mmol/l) and LDL-cholesterol (6.5mmol/l) in 
FH-M+ were significantly higher than FH-M- (p<0.001). There was no 
significant difference in triglyceride levels between the two groups. The 
clinical hallmarks of FH such as tendon xanthomatas and corneal arcus 
showed no significant difference between the groups probably due to the 
presence of missing data. 
 
Table 5. Basic characteristics of FH patients 
 
 
Total n=322 FH-M+ n=214 FH-M- n =108 Sig. M+ vs M- 
Men 127/195 (39.4%) 86/128 (40%) 41/67 (38%) ns 
Age (years)  33 ± 18 30.5 ± 17.4 37.8 ± 18.6 p=0.001 
Total cholesterol (mmol/L) 7.9 (7.1-9.2)  8.3 (7.4-9.6) 7.4 (6.7-8.1) p<0.0001 
LDL-cholesterol (mmol/L) 5.0 (6.1-7.1)  6.5 (5.5-7.6) 5.2 (4.5-5.8) p<0.0001 
HDL-cholesterol (mmol/L) 1.3 (1.1-1.7)  1.3 (1.1-1.6) 1.4 (1.2-1.8) p=0.01 
no-HDL –Cholesterol 
(mmol/L) 6.6 (5.5-7.7)  7.0 (5.9-8.1) 5.8 (5.1-6.5) p<0.0001 
Triglycerides (mmol/L) 1.1 (0.8-1.6)  1.0 (0.8-1.5) 1.2 (0.9-1.6) ns 
Carotid thickning n (%) 49 (40.5) 36 (43.0) 13 (40.0) ns 
Tendon xanthomas n (%) 21 (13.9)  18 (16.0) 3 (7.0) ns 
Corneal arcus n (%)  17 (18.5)  14 (21.0) 3 (13.0) ns 
Carotid Atherosclerotic 
plaques n (%) 20 (16.5)  17 (10.0) 3 (19.0) ns 
Smoker (%) 43 (26.5)  27 (41) 16 (22) ns 
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4.2 Mutations in the FH causative genes 
 
In our cohort we found mutations in 214/322 unrelated subjects (mutation 
rate 66.5%). 
All patients with APOB or PCSK9 mutations were heterozygotes; whereas 
among patients with LDLR mutations there were 3 homozygotes (two 
identical mutations, 1%) and 7 compound heterozygotes (with different 
mutations on each LDLR allele, 2%). The total number of unrelated patients 
with 2 mutations was 10/322 (3.1%). (Fig.7) 
The frequency of homozygotes/compound heterozygotes in the total 
population was 17/432 (4 homozygotes, 13 compound heterozygotes) 
3.9%.  
 
 
 
Figure 7. Distribution of mutations  in LDLR, ABPO, PCSK9 genes 
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4.3 Spectrum of mutations in LDLR, APOB, PCSK9 genes 
 
4.3.1 Mutations in the LDLR gene 
 
Among 214 mutated subjects, 204 (95.3%) were carriers of LDLR 
mutations, 6 (2.8%) of APOB mutations and 4 (1.8%) of PCSK9 mutations. 
All mutations in APOB and PCSK9 were missense mutations. 
Among 204 patients with mutations in the LDLR gene we found 214 
mutations of which 122 missense (57.0%), 15 nonsense (7.0%), 57 splicing 
(26.6%), 7 small rearrangements including small deletion, small 
deletion/insertion (3.3%) and 1 regulatory (0.46%).  
Furthermore direct sequencing revealed 58 different mutations, 15 present 
only in this cohort. We carried out a MLPA analysis to search for large 
rearrangements and we found gross deletions in 12/214 mutations (5.6%) 
as shown in figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Number of mutation types identified in our cohort 
 
Among the 58 different mutations found, 6 mutations accounted for more 
than 50% of cases. The most commonly observed mutations in the LDLR 
gene were c.1775G>A (p.Gly592Glu) was found in 31 patients (15.2%), the 
splicing mutation in intron 15 c.2312-3C>A (causing exon 16 skipping:  
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p.Ala771_796del) was found in 28 patients (13.7%), the splicing mutation in 
intron 10 c.1586+1G>A (causing exon 10 skipping: p.Thr454_Gly529del 
and retention of intron 10: p.Gly529_Phe530ins22) was found in 19 patients 
(9.3%), the missense mutation c.1567G>A (p.Val523Met) was  found  in 16 
patients (7.8%) and c.1646G>A (p.Gly549Asp) was found in 15 patients 
(7.3%). In table 5 are reported the 58 different mutations. 
 
Table. 5 LDLR mutations identified in our population. 
 
Position Mutation type Nucleotide Protein Frequency 
Promoter Regulatory c.1-156 C>T — 1 
Exon 1 Missense c.58G>A p.Gly20Arg 1 
Exon 2 Nonsense c.116_117delGCinsAA p.Cys39X 4 
Exon 2 Missense c.102C>G p.Cys34Trp 1N 
Exon 3 Nonsense c.304C>T p.Gln102X 5 
Intron 3 Splicing c.313+1G>A p.Leu64_Pro105delinsSer 1 
Exon 4 Missense c.352G>T p.Asp118Tyr 2 
Exon 4 Missense c.367T>C p.Ser123Pro 5* 
Exon 4 Deletion c.369_370delTC p.Ser123fsX6 2 
Exon 4 Missense c.407A>T p.Asp136Val 2* 
Exon 4 Deletion c.424_430delTCCTGCC p.Ser142ArgfsX62 2 
Exon 4 Missense c.440C>T p.Thr147Ile 2 
Exon 4 Missense c.465C>A p.Cys155X 9 
Exon 4 Missense c.514G>A p.Asp172Asn 1 
Exon 4 Missense c.542C>G p.Pro181Arg 2 
Exon 4 Missense c.662A>G p.Asp221Gly 1 
Intron 4 Splicing c.694+1G>C IVS4+1G>C 1 N 
Exon 5 Missense c.761A>C p.Gln254Pro 1 
Exon 6 Missense c.859G>T p.Gly287Cys 2 
Exon 6 Missense c.892 A>G p.Met298Val 1 N 
Exon 7 Missense c.953G>T p.Cys318Phe 1 
Exon 7 Missense c.974G>A p.Cys325Tyr 2 
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Position Mutation type Nucleotide Protein Frequency 
Exon 7 Missense c.1003G>A p.Gly335Ser 1 
Intron 7 Splicing c.1060+10 p.asp333GlyfsX20 1 
Intron 8 Splicing c.1061-8T>C IVS7-8 T>C 1 
Exon 8 Nonsense c.1070_1071dupAG p. p.Cys358SerfsX13 2 N 
Exon 8 Missense c.1118G>A p.Gly373Asp 3 
Exon 8 Missense c.1130G>T p.Cys377Phe 4* 
Exon 8 Missense c.1135T>C p.Cys379Arg 16* 
Intron 8 Splicing c.1187-10G>A p.Gly396AspfsX19 3 
Exon 9 Missense c.1211C>T p.Thr404Ile 1 
Exon 9 Missense c.1215C>G p.Asn405Lys 1 
Exon 9 Missense c.1216C>A p.Arg406Arg 1 
Exon 9 Missense c.1247G>C p.Arg416Pro 2 
Exon 9 Missense c.1277T>G p.Leu426Arg 2 N 
Exon 9 Missense c.1295T>C p.Leu432Pro 1 
Exon 9 Missense c.1331C>T p.Ser444Phe 1 
Exon 10 Deletion c.1478_1479delCT p.Ser493CysfsX42 3* 
Exon 10 Missense c.1558A>G p.Arg520Gly 1 
Exon 10 Missense c.1567G>A p.Val523Met 21* 
Intron 10 Splicing c.1586+1G>A 
p.Thr454_Gly529del 
and 
p.Gly529_Phe530ins22 
25* 
Exon 11 Missense c.1646G>A p.Gly549Asp 20* 
Exon 11 Missense c.1694G>T p.Gly565Val 1 
Exon 11 Deletion/Insertion c.1698_1704delinsGCCCAAT 
p.Ile566_Leu568 
delinsMetProAsn 1 
Exon 11-12 Large deletion c.1587-?_1845+?del p.Phe530ThrfsX49 10 
Exon 12 Missense c.1730G>C p.Trp577Ser 3 
Exon 12 Missense c.1739C>T p.Ser580Phe 6* 
Exon 12 Missense c.1775G>A p.Gly592Glu 48* 
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*indicates the presence of a mutation  in a compound heterozygotes or in 
homozygotes 
N
 indicates a novel variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position Mutation type Nucleotide Protein Frequency 
Exon 13 Missense c.1898G>A p.Arg633His 1 
Exon 13-15 Large deletion c.1846-?_2140+?del p.Asp616ArgfsX16 1 
Exon 13-15 Large deletion c.1846-?_2311+?del p.Asp616LeufsX17 8 
Exon 14 Missense c.2054C>T p.Pro685Leu 6* 
Exon 15 Splicing c.2311+1G>A IVS15+1G>A 1 
Exon 15 Nonsense c.2215C>T p.Gln739X 1 
Intron 15 Splicing c.2312-3C>A p.Ala771_Ile796del 47* 
Exon 16 Missense c.892A>G Met298Val 1 
Exon 16 Missense c. 2389G>A p.Val797Met 3 
Exon 17 Missense c.2476C>A p.Pro826Thr 2* 
40 
 
Variations were detected along the entire LDLR gene (Fig.9). To estimate 
the frequency of mutations by exon compound and multiple mutations we 
considered them separately. Exon 10 had the highest frequency of 
mutations (20%), while the frequency in exon 12 and exon 16 was 19.1%-
15.1% respectively. Exon 4 (10.3% frequency of mutation) was more 
susceptible to suffer modifications since it had approximately 17 different 
mutations, which is the highest number of different mutations reported in 
exons . The other exons were less susceptible to modifications with a very 
low  mutation frequency.  
Figure 9. Frequency of point mutations distributed along the LDLR gene 
 
In this study were found 5 novel variations which were not reported in the 
FH database. Three new variations were a single nucleotide change 
(c.102C>A; c.892A>G; c.1277T>G) resulting in aminoacid substitution 
p.Cys34Trp; p.Met298Val; p.Leu444Arg respectively. These missense 
variations affect aminoacid residues conserved across the homologous LDL 
receptor proteins from 12 different examined species (chimpanzee, gorilla, 
orangutan, cat, rat, mouse, guinea pig, macaque, dog, pig, cow and 
zebrafish).  
One involved in intron 4 splice donor site (c.694+1G>C), reverse 
transcription and PCR amplification ware performed for variant 
c.694+1G>C. The band corresponding to the skipping of exon 4 was more 
intense than that observed in our control, thereby confirming the reduced 
use of the donor splice site. We also observed three bands not detectable 
in the healthy control.  
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One small duplication of AG in exon 8 (c.1070_1071dupAG) predicting 
frame shift and premature termination. 
 
4.3.2 Mutations in the APOB gene 
 
In the APOB gene group, direct sequencing of exons 26-29 revealed four 
different mutations (c.9916G>A, c.10672C>T c.10897T>C c.12536C>G)  
resulting in aminoacid substitution p.Val3306Ile p.Arg3558Cys 
p.Trp3633Arg p.Thr4179Ser respectively (Table 6).  
Two of them p.Val3306Ile and p.Trp3633Arg were novel variations. These 
mutations affect aminoacid residues conserved across the homologous 
APOB proteins and were searched in Exome Sequencing Project (ESP), 
none of which was included in ESP. 
 
Table 6. Mutations identified in the APOB gene 
 
Position Mutation type Protein Frequency 
26 Missense  c.9916G>A p.Val3306Ile* 1 
26 Missense c.10672C>T p.Arg3558Cys 1 
29 Missense c.10897T>C p.Trp3633Arg* 1 
29 Missense c.12536C>G p.Thr4179Ser 3 
 
* Novel variation 
 
4.3.3 Mutations in the PCSK9 gene 
 
In the PCSK9 gene group, direct sequencing of the 12 encoding region 
revealed four different mutations (c.991C>G c.1069C>T c.1394C>T 
c.1496G>A) resulting in aminoacid substitution p.Pro331Ala, p.Arg357Cys 
p.Ser465Leu,  p.Arg499Hys respectively (Table 7).  
Two were known mutations p.Arg357Cys, p.Ser465Leu and other two were 
novels p.Pro331Ala p.Arg499Hys.  
These mutations affect aminoacid residues conserved across the 
homologous PCSK9 proteins and were searched in Exome Sequencing 
Project (ESP), none of which was included in ESP. 
The functional characterization of p.Ser465Leu was performed as 
described in our previously paper [81]. 
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Table 7. Mutations identified in PCSK9 gene 
 
Position Mutation type Protein Frequency 
6 Missense c.991C>G p.Pro331Ala* 1 
7 Missense c.1069C>T p.Arg357Cys 1 
9 Missense c.1394C>T p.Ser465Leu 1 
9 Missense c.1496G>A p.Arg499Hys* 1 
 
* Novel variation 
 
4.5 In silico analysis of the LDLR, APOB, PCSK9 mutations 
 
In silico analysis of the novel mutations of the three genes is  shown in 
table 8.  
In the case of LDLR, only the missense mutation p.Cys34Trp resulted to be 
pathogenic for four algorithmics. The mutation p.Leu444Arg resulted to be 
pathogenic based on the consensus of PolyPhen2, SIFT, Mutation Taster, 
resulted neutral for PMut algorithms. The splicing mutation c.694+1G>C 
was predicted to abolish the donor splice site by all the 5 algorithms used. 
In silico analysis was not applicable for duplication of AG in exon 8 and it 
was assessed using conservation and structure analysis.  
The causative role of  mutations in the APOB and PCSK9 genes resulted 
uncertain based on the consensus of four algorithms, were considered to 
be possibly damaging on the basis of indirect criteria such as the aminoacid 
conservation across the homologous proteins and the segregation with the 
FH phenotype.  
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Table 8. In silico prediction of the effect of variants in LDLR, APOB, PCSK9 genes   
 
              D–probably damaging (PolyPhen2), damaging (SIFT), disease causing (Mutation Taster), pathological (PMut) 
              P–possibly damaging 
              B–benign(PolyPhen2), tolerated (SIFT), polymorphism (Mutation Taster), neutral (PMut) N/A–not applicable
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4.6 Correlation between lipid levels, mutation type and clinical criteria  
 
4.6.1 Differences in lipid levels between mutation type/number of mutations 
 
To evaluate the influence of the LDLR mutations on the phenotype, the 
patients were divided into four groups: no mutation, carrier of missense 
mutation, carrier of one radical mutation, homozygotes/compound 
heterozygotes.  
The missense carrier group included only the single nucleotide change 
resulting in aminoacid substitution, whereas the radical mutation group  
included carriers of small deletions (with frame shift effect), large deletions 
(deletion of entire exons), splicing mutations (causing exon skipping or 
intron retention), nonsense mutations (giving rise to a premature stop 
codon producing a truncated protein. 
Levels of TC and LDL-C gradually increased in the four group of patients. 
All of these differences in TC and LDL-C were statistically significant at 
Kruskal Wallis test (p<0.0001).  
Multiple testing by Bonferroni correction revealed statistical differences 
between each group versus the others (Table 9). 
There was no significant difference in TG and HCL-C levels between the 
four groups.
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Table 9. Differences between lipid levels and mutations type  
 
Miss= missense, Rad= radical, Comp= Homozygotes/Compound heterozygotes 
ns= not significant
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4.6.2 Differences in lipid levels between groups based on DCLN diagnosis 
  
The DCLN criteria cannot be used in children, for this reason an unrelated 
paediatric cohort was removed from the analysis and therefore DCLN score 
was available only for 254 patients.  
According to DCLN criteria, patients were divided into four groups: definite-
FH (subjects with score >8 points), probable-FH (subjects with scores 6-8 
points), possible-FH (subjects with scores 3 to 5 points) and no FH 
(subjects with scores 0-2 points). 
Levels of TC and LDL-C gradually increased from patients without 
mutations to patients with a possible-FH, to patients with a probable-FH 
and to patients with a definite-FH. All  these differences in TC and LDL-C 
were statistically significant at Kruskal Wallis test (p<0.0001).  
Multiple testing by Bonferroni correction revealed statistical differences 
between each group versus the others (Table 10). 
There was no significant difference in TG and HCL-C levels between the 
four groups. 
 
.  
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Table 10. Differences in lipid levels among groups based on DCLN diagnosis 
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4.6.3 Lipid levels differences among groups based on the Simon Broome 
diagnosis 
 
Since the Simon Broome diagnostic criteria for FH include pediatric 
subjects a pediatric cohort was also included in our analysis . According to 
these criteria our cohort was divided into three groups:  possible-FH, 
probable-FH and no-FH. In this last group we included subjects with TC 
and LDL-C levels above the Simon Broome criteria cut off (7.5mmol/l 
and/or 4.9mmmol/l respectively) but without family history that could be 
clarified.  
Table 11 shows that levels of TC were not significantly  different between 
definite-FH and possible-FH group at  Bonferroni test. This difference was 
statistically significant at Kruskal Wallis test (p=0.002) in all groups.  
On the contrary levels of LDL-C gradually increased from patients without 
mutation to patients with a possible-FH and to patients with a definite-FH. 
Multiple comparisons by Bonferroni correction revealed statistically 
significant  differences between each group versus the others (p=0.0026), 
Kruskal Wallis test revealed a significant difference between groups 
(p=0.001).  
There was no significant difference in TG and HDL-C levels between the 
three groups 
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Table 11. Differences in  lipid levels among groups based on the Simon Broome diagnosis 
 
 
no-FH  Significant at Bonferroni test possible-FH 
Significant at 
Bonferroni test definie-FH  
Significant at 
Kruskal Wallis 
TC (mmol/L) 7.6 (6.6-8.7) Sig vs pos p=0.030 Sig vs def p=0.002 8.1 (7.4-9.2) Sig vs def p=0.088 8.5 (6.9-11.4) p<0.0001 
LDL–C 
(mmol/L) 5.4 (4.6-6.4)  
Sig vs pos p=0.025 
Sig vs def p<0.0001 6.3 (5.3-7.2) Sig vs def p=0.026 6.8 (9.6-4.7) p=0.001 
HDL-C 
(mmol/L) 1.3 (1.2-1.7)  
Sig vs pos p=ns 
Sig vs def p=0.014 1.3 (1.1-1.6) Sig vs def p=0.080 1.1 (1.0-1.4) p=0.039 
no-HDL-C 
(mmol/L) 6.0 (4.9-6.8)  
Sig vs pos p=0.014 
Sig vs def p<0.0001 6.8 (5.8-7.7) Sig vs def p=0.011 7.7 (5.5-10.0) p<0.0001 
TG (mmol/L)  Sig vs pos p=ns Sig vs def p=ns  Sig vs def p=ns  p=ns 
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4.7 Relation between diagnosis criteria and mutations 
 
4.7.1 DCLN diagnosis and mutations 
 
The number of patients in which mutations were found according to the 
DCLN score is show in figure 9. The highest  number of positive patients 
was obtained when their clinical diagnosis was definite-FH. As expected, 
the frequency of FH-M+ increased as increased the score from no FH group 
to possible, probable and to definite-FH. Patients without detected 
mutations were mainly in no FH group (59%) or in possible FH group 
(33%).  
However, there was one patient with a definite-FH score but without any 
detected mutation. 
 
 
 
Figure. 9 Percentage of patients with or without mutation, classified by 
DCLN score  
 
Furthermore, when mutations were considered on the basis of the mutation 
type (missense, radical homozygotes/compound heterozygote) we 
observed that the missense mutation had the same distribution among the  
four  score groups (Fig.10).  
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In the groups of probable-FH and definite-FH  we observed the highest 
frequency of the radical and homozygotes/compound heterozygote 
mutations that caused more severe phenotypes. However, patients (10%) 
with a radical mutation were present also in the no-FH group.  
In the groups of possible-FH and no FH  there was no the presence of 
patients with homozygotes/compound heterozygote mutations .  
 
 
 
 
Figure 10. Distribution of mutation types according to DCLN score 
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4.7.2 Simon Broome diagnosis and mutations 
 
The number of patients in which mutations were found according to the 
Simon Broome diagnostic criteria is show in figure 11. The highest  number 
of positive patients was obtained when their clinical diagnosis was definite-
FH. As expected, the frequency of FH-M+ increased as increased the score 
from no FH group to possible, probable and to definite-FH. Patients without 
detected mutations were mainly in no FH group (49%) or in possible FH 
group (27%). However, in the group with uncertain diagnosis (no-FH) we 
found mutations in 51% .  
This was possible because in this group we included patients with TC and 
LDL-C levels above the Simon Broome criteria cut off (7.5mmol/l and/or 
4.9mmmol/l respectively) but without family history that could be clarified.  
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure11. Percentage of pa52tients with or without mutations, classified by 
Simon Broome criteria 
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Furthermore, when mutations were considered on the basis of mutation 
type (missense, radical, homozygotes/compound heterozygote) we 
observed that the missense mutations had the same distribution between 
possible-FH and definite –FH groups (Fig.12).  
In the group of no-FH there were 27% of patients with missense mutation 
and 24% with radical mutation. 
However there were no a homozygotes/compound heterozygote in the 
group of no-FH.   
 
 
 
 
 
 
 
Figure 12. Distribution of mutation type according  Simon Broome criteria 
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4.7.3 DCLN score vs Simon Broome criteria  
 
The Chi-Quadrat Test analysis was used to compare the DCLN score and 
Simon Broome criteria. The two criteria were overlapping in the 68% of 
cases, showing a concordance of the 20.8% to classify the FH-M- in the no-
FH group, a concordance  of the 42.1% to classify  the FH-M+ in the 
possible-FH group  and of the 5.1% to classify  the FH-M+ in the definite-
FH group.  
The differences were due to the presence of  patients (16.1%) classified as 
probable/possible-FH  on the base of the DCLN score but classified as no-
FH  on the base of the Simon Broome criteria. 
Furthermore, there were two patients classified as definite-FH for DCLN 
score but no-FH for Simon Broome criteria. The patients show mutations in 
the LDLR gene. This difference in the classification could to be due to  
different clinical hallmarks of FH using the two diagnostic criteria. One 
patient presented corneal arcus and the other patient presented carotid 
atherosclerotic plaques. These clinical hallmarks of FH were not evaluated 
by Simon Broome criteria. For DCLN criteria the presence of corneal arcus 
assigns a score of 4 and the presence of  carotid atherosclerotic plaques 
assigns a score of 2. These scores added to biochemical results allowed to 
establish the highest score of 8, classifying the patients with a  definite-FH 
diagnosis. 
 
Table 12 . Comparison between DCLN score and Simon Broome criteria 
 
Si
m
o
n
 
B
ro
o
m
e 
c
rit
er
ia
 
 Dutch Lipid Clinic Network 
no-FH possible/probable-FH definite-FH 
no-FH 53 (20.8%) 41 (16.1%) 2 (0.8%) 
possible-FH 20 (7.8%) 107 (42.1%) 10 (3.9%) 
definite-FH 0 (0) 8 (3.1%) 13 (5.1%) 
 
 
 
 
55 
 
4.8 Polygenic 
 
4.8.1 LDL-C gene score analysis 
 
We enrolled 199 patients with clinically diagnosed FH, of whom 160 were 
unrelated. The screening revealed mutations in 141 patients. The mean 
levels of TC and LDL-C was above 95th percentile (8.13 ± 2.12, 6.25 ± 2.13) 
respectively. Out of 199 FH samples (141mutation positive, 58 mutation 
negative), genotyped for all 12 SNPs, patients with polygenic FH with a 
gene score above 1.16 cut off were 10/141 (7.1%) FH/M+, 5/58(8.6%) 
FH/M-. 
The familial hypercholesterolemia group without a known mutation had a 
significantly higher mean weighted LDL-C gene score of 0.96 (SD 0·21; 
p=0.0046) than did WHII participants. This suggests that a substantial 
proportion of the mutation-negative familial hypercholesterolemia group’s 
raised LDL-C concentrations can be explained by co-inheritance of 
common LDL-C-raising SNPs.  
When we calculated the weighted LDL-C gene score in the familial 
hypercholesterolemia group with a known mutation, the mean weighted 
score (0·93 [SD 0·20]) was significantly higher than the score in the WHII 
group (0·89 [0·23]; p=0.057, but was not significantly lower than that of the 
mutation-negative group (0.96 [0·21]) (Fig.13). This result suggests that 
even in patients with familial hypercholesterolemia who have a detected 
causative mutation, their raised LDL-C concentrations have an additional 
polygenic component.  
Overall, 73 (16%) had a LDL-C gene score that fell within decile 10 of the 
WHII LDL-C gene score distribution, and 211 (46%) fell within deciles 7–10. 
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Figure 13. Comparison of the LDL-C SNPs score between the WHII 
control populations, the FH mutation positive individuals, the FH mutation 
negative individuals in a standard box-plot. Dashed red line indicates the 
top of decile cut off 1.16 for the WHII cohort.  
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4.9 Paediatric cohort 
 
4.9.1 Patients characteristics 
 
87 unrelated patients were included in the paediatric cohort (total 
populations 99 subjects). The mean age was 9.7 ± 3.8, the clinical 
characteristics of patients enrolled were reported in table 13.  
All lipid parameters showed parametric distributions, the data was reported 
as mean±SD. The mean levels of total cholesterol (7.8mmol/l) and of LDL-
cholesterol (5.7mmol/l) in FH-M+ were  significantly higher than FH-M- 
(p=0.002, p<0.001 respectively). There was no significant difference in 
triglyceride levels between two groups. The clinical hallmarks showed no 
significant difference between the groups probably due to the presence of 
missing data. 
 
Table 13 . Basic characteristics of paediatric FH patients 
 
 
Among 87 patients, there were 24 subjects no-FH (27.6%), 56 possible-FH 
(64.4%) and 7 with definite-FH (8%). in the group no-FH  42% of patients 
shows missense mutations and 21% show radical mutations but subjects 
with homozygotes/compound heterozygotes were absent. The missense 
mutation had a  higher frequency in possible-FH than other groups. Among 
three patients with homozygotes/compound heterozygotes two were 
classified into possible-FH and one into definite-FH showing a frequency of 
4% and 14% respectively (Table 14).  
Table 15 showed that levels of TC and LDL-C gradually increase from 
patients without mutation to patients with a missense mutation, to patients  
 
Total n=99 FH-M+ n=65 FH-M- n =22 Sig. M+ vs M- 
Age (years)  9.7 ± 3.8 9.5 ± 3.9 10.18± 3.5 ns 
Total cholesterol (mmol/L) 7.8 ± 2.3  8.3 ± 2.4 6.4 ± 1.1 p=.0.002 
LDL-cholesterol (mmol/L) 5.7 ± 2.1  6.3 ± 1.9 4.0 ± 1.6 p<0.0001 
HDL-cholesterol (mmol/L) 1.3 ± 0.3  1.2 ± 0.2 1.5 ± 0.4 ns 
no-HDL –Cholesterol (mmol/L) 6.3 ± 2.0  6.8 ± 2.0 4.9 ± 1.2 p<0.0001 
Triglycerides (mmol/L) 0.9 (0.7-1.2) 0.9 (0.7-1.1) 1.0 (0.7-1.4) ns 
Corneal arcus 1 (2.5) 1 (3.3) 0 (0.0) ns 
Tendon xanthomas (%) 5 (8.5) 3 (6.5) 2 (15.4) ns 
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with a radical and to patients with homozygotes/compound heterozygotes. 
All  these differences in TC and LDL-C were statistically significant at 
Kruskal Wallis test (p<0.0001).  
Multiple testing by Bonferroni correction revealed statistical differences 
between each group versus the others. In particular the mean of TC  levels  
in subjects with homozygotes/compound heterozygotes was double 
compared to patients with a missense mutation. There was no significant 
difference in TG and HCL-C levels between four groups. 
 
Table 14. Frequency of mutation type among Simon Broome criteria in 
pediatric cohort 
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Table 15. Lipid levels differences among groups based on Simon Broome criteria in a pediatric cohort. 
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5. Discussion 
 
In the attempt to identify genetic background among patients with clinically 
diagnosed FH, 322 unrelated patients were screened for LDLR, APOB and 
PCSK9 genes, according to studies that underlined how the molecular 
analysis plays a key role to confirm the diagnosis. The identification of 
individuals with FH, as early as possible, is important to improve their 
therapeutic approach and drug monitoring, in fact subjects between 20 and 
39 years old have 100-fold increased risk to develop premature CHD 
compared to the normal population. 
The main features of genetic FH are the high mutation heterogeneity and 
presence of mutations clusters across different geographic areas. 
In our cohort, the mutations have been found in 214/322 subjects with a 
mutation rate of 66% in agreement with other studies ([78], [79]. 
Out of 214 mutated subjects about 95.3% were carriers of LDLR mutations, 
2.8% of APOB mutations and 1.8% of PCSK9 mutations. The distribution of 
the mutations across the three candidate genes is similar to that reported in 
other Italian studies (97.4% LDLR, 2.2% in APOB and 0.36% in PCSK9) 
[82] while is little different  to that reported in French cohort studies  (73.9% 
LDLR, 6.6% in APOB and 0.7% in PCSK9) [83] and Dutch cohort studies 
(88% LDLR, 12% in APOB and no mutation in PCSK9) [84].  
The main difference between these studies is the percentage and the type 
of mutation identified in APOB gene. The p.Arg3500G mutation is 
frequently detected in French and Dutch cohort. The Arg3500Gln mutation 
in the APOB gene  is the most common cause of hypercholesterolemia, 
accounting for 5 to 10% of FH cases in Northern European populations [8] 
but its frequency is very low in the Latin European population compared 
with Central European population [35]. 
The genetic screening performed in FH patients demonstrated that LDLR 
gene shows  a genetic heterogeneity in our population. Regarding the ApoB 
gene, through direct sequencing of exon 26 and 29 we identified four 
different mutations of which two novels (p.Val3306Ile and p.Trp3633Arg ). 
The pathogenic role of the novel variations found in the APOB gene  was 
supported by in silico analysis only for p.Val3306Ile. In a recent study 
Thomas et al [85] reported that a new mutation (p.Arg50Trp) identified in 
exon 3 of APOB causes hypercholesterolemia, underlining the importance 
to perform a complete screening for all the involved exons although the cost 
is still high. 
In the PCSK9 gene we found four different variations (p.Pro331Ala, 
p.Arg499Hys novels) but we did not find the most frequent mutation 
(p.Asp374Tyr), which is associated with a higher CHD [86]. In silico  
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analysis of variants in PCSK9 suggested that its effect was uncertain. 
Variants could influence  the functionality of the protein, although these 
algorithms cannot predict the GOF or LOF effect. In fact, it has been 
reported that predictions of GOF mutations should be interpreted with 
caution [87] due to  the inaccuracy of the prediction tools. Functional 
characterization is necessary to evaluate the functional effect of these 
variants. 
In LDLR the variations were detected along the entire gene. The UCL FH 
database (www.ucl.ac.uk) reported a different frequency of mutation on the 
exons. A greater number of different mutations were detected in exon 4 
which is more susceptible to suffer modifications because of its length. 
However, the highest frequency of mutations in our cohort was identified in 
exon 10, exon 12, and exon 16. Mainly, the highest frequency of mutations 
in these exons is due to the presence of common LDLR gene mutations 
which are typical of southern Italian regions. The number of LDLR 
mutations accounting for the FH phenotype varies among European 
countries [88], [83]. In Italy, more than 237 mutations have been reported 
so far, some of which are present only in some Italian regions [82].  
In Southern Italy the 6 most frequent mutations account for more than 50% 
of cases. The c.1775G>A mutation, most common in our cohort, has also 
been described in Greek and German FH patients [89]. The second most 
common mutation (13.7%) is c.2311+G>A, these data agree with previous 
reports, suggesting a founder effect in our region for this mutation [90].  
Among the 58 different mutations, 15 have been found in our population for 
the first time, out of which 10 have been already published [91], [34] and 5 
are novels.  
The p.Cys34Trp mutation, is involved the ligand-binding domain. In 
particular, is one of six cysteine residues that forms LA repeat 4 that LDL-
receptor used to bind APOE on chylomicrons. The p.Met298Val was found 
in compound heterozygotes together with splicing mutation 
p.Ala771_Ile796del. 
The mutation p.Leu444Arg occurs at the same codon as that previously 
described for the c.1330T>C (p.Leu444Pro) mutation and it affects a highly 
conserved aminoacid located in the EGF precursor homologous domain 
[92].  
Regarding mutation splicing c.694+1G>C, the analysis of RNA from the 
patient confirmed the less use of the donor splice site and the presence of a 
splicing alteration in intron 4. The transcript corresponding to the skipping of 
exon 4 was also identified in healthy subjects [93], [94] and in our control 
although at lower levels than the mutated sample. In addition, three bands 
not detectable in the healthy control were observed on the gel, which  
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suggests that the use of cryptic splice sites causes a dramatic decrease in 
the amount of full length mRNA. 
The small duplication of AG, p.Cys358SerfsX13 is involved in the EGF –like 
domain. The EGF –like domain is responsible for the dissociation of LDLR 
from the LDL in the endosome at low pH, [26]. This mutation could to 
prevent recycling of the receptor to the cell membrane. 
Although there is a high frequency of common mutations, we recommend 
performing the complete genetic screening aimed at identifying new or rare 
mutations as well as patients with two mutations. In fact, to prevent fatal 
cardiovascular events, particular attention should be paid to  the 
identification of compound heterozygous and homozygous patients . 
In addition, we examined the reliability of the Dutch Lipid Clinic Network 
(DCLN) score and Simon Broome criteria, to identify patients with a high or 
low probability of carrying an FH-causing mutation. Using the DCLN score, 
we found that the percentage of FH-M+ classified as definite-FH is 96%, 
classified as probable-FH or possible-FH are 81.3% and 66.9% respectively 
and patients FH-M+ classified as no-FH is 41.1%.  
Using the Simon Broome criteria, we found that the percentage of FH-M+ 
classified as definite-FH is 88.5%, classified as possible-FH are 73.2% and 
FH-M+ classified as no-FH is 51.3%. Patients with mutations in the APOB 
gene are classified as no-FH for both diagnosis criteria. These results could  
be due to mutations in the APOB gene that show a less severe phenotype 
than the mutations in the LDLR gene [94].  
The DCLN criteria are more accurate than Simon Broom showing very high 
sensitivity and specificity to detect patients with mutations. 
Furthermore, the comparison of the two diagnostic criteria revealed an 
overlapping between possible-FH and possible-FH/probable-FH groups for 
both criteria. However we found two patients with mutations in the LDLR 
gene classified as definite-FH on the basis of DCLN score and no-FH on 
the basis of Simon Broome criteria. This result is probably due to the fact 
that the Simon Broome criteria do not take into account physical 
examinations such as corneal arcus, carotid atherosclerotic plaques and 
clinical history of CHD. Therefore, Simon Broome criteria are easy to apply 
and they can sometimes lead to a missed diagnosis.  
Additionally, a proportion of patients (199 subjects) were analyzed for 12 
common SNPs that the Global Lipid Genetic Consortium (GLGC) reported 
as significantly associated with LDL-C. The cumulative effect of common 
LDL-rising alleles in these genes was shown to be likely cause of high LDL-
C in a proportion of examined patients. These results confirm the previous 
report by Talmud et al, and show that, also in Italian patients with the FH 
phenotype but without mutations in the main candidate genes, there is a 
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likely polygenic cause, due to the inheritance of LDL-C-raising SNPs which 
increases LDL-C concentration in patients. This polygenic contribution is 
also seen in patients with detected FH-causing mutations.  
We examined also a cohort of children exposed to fewer environmental 
factors  in terms of their lipoprotein metabolism in which an unequivocal 
diagnosis of FH is easier to establish. In this population we observed the 
gradually increase of the TC and LDL-C among patients with different types 
of mutation showing  that  the type of the LDLR mutation influences the lipid 
profile. Patients with radical mutations show a worse lipid profile than 
missense carriers allowing a prognostic evaluation for physicians. 
In conclusion, the results of this study represent an update of FH genetic 
background in an Italian population of patients from southern regions. 
These data enlarge the spectrum of mutations causing FH and highlight the 
importance of a complete screening of causative genes in order to identify 
more or novel mutations and to identify homozygotes/compound 
heterozygotes. 
The correlation between mutation types and lipid profile underlines 
importance of genetic screening as  a prognostic tool. 
The presence of a percentage of mutated subjects in the no-FH group 
according to Dutch Lipid Clinic Network (DCLN) score and Simon Broome 
criteria suggests that genetic screening is also useful to confirm the 
diagnosis, especially in patients with an uncertain phenotype. 
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Objective:Autosomal dominant hypercholesterolemias are due to defects in the LDL receptor (LDLR) gene,
in the apolipoprotein B-100 gene or in the proprotein convertase subtilisin/kexin type 9 gene. The aim
of this study was to identify and functionally characterize mutations in the LDLR gene that account for
most cases of familial hypercholesterolemia (FH).
Methods:Weenrolled 56 unrelated patients from Southern Italywith a clinical diagnosis of FH. Themuta-
tion screeningwasperformedbydirect sequencingof thepromoter and the18exons of the LDLRgene and
bymultiplex ligation-dependent probe amplification (MLPA) analysis to search for large rearrangements.
Results and conclusion: We found 5 new mutations, the causative role of which was demon-
strated by functional characterization performed by quantification of fluorescent LDL uptake in
EBV-transformed B lymphocytes. These results enlarge the spectrum of FH-causative LDLR muta-
tions. Lastly, screening for large rearrangements is highly recommended for the genetic diagnosis of
FH.
© 2009 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Autosomal dominant hypercholesterolemias are a hetero-
geneous group of genetic lipid disorders characterized by
high levels of total and low-density lipoprotein (LDL) choles-
terol. Causes of autosomal dominant hypercholesterolemias
include defects in the LDL receptor (LDLR) gene, in its ligand
apolipoprotein B-100 (ApoB), or in the proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) gene [1]. The genetic
defect remains unknown in a small percentage of FH patients
[1].
More than 1200 mutations in the LDLR gene, at 19p13.1-p13.3
(MIM #606945), have been identified worldwide in FH patients
(http://www.ucl.ac.uk/fh and http://www.umd.necker.fr); these
∗ Corresponding author at: Dipartimento di Biochimica e Biotecnologie Mediche,
Università degli Studi di Napoli Federico II, via Pansini 5, 80131, Napoli, Italy.
Tel.: +39 0817464200; fax: +39 0817462404.
E-mail address: fortunat@unina.it (G. Fortunato).
include single-nucleotide mutations, duplications, deletions and
splicing alterations [2].
The aim of this study was to identify and functionally charac-
terize mutations in the LDLR gene in patients from Southern Italy
with a clinical diagnosis of FH.
2. Materials and methods
2.1. Patients
Fifty-six unrelated patients from Southern Italy with clinically
diagnosedFHwereenrolledat theDipartimentodiMedicinaClinica
e Sperimentale, Università degli Studi di Napoli Federico II. Rela-
tives of 14/56 subjects were available. The FH diagnosis was based
on the criteria established by the Società Italiana per lo Studio
della Arteriosclerosi for the identification and treatment of dyslipi-
demias. The study was performed according to the current version
of theHelsinkiDeclaration. Informedconsentwasobtained for each
patient. The demographic and biochemical features of the patients
are reported in Supplemental table.
0021-9150/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.atherosclerosis.2009.11.051
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2.2. Biochemical analysis
Biochemical markers were measured as described in
Supplemental methods
2.3. Mutation screening
2.3.1. DNA sequencing of LDLR gene
Genomic DNA was isolated from whole blood EDTA samples
using the Nucleon BACC2 kit (Amersham). The promoter and the
18 exons of the LDLR gene were amplified by PCR and directly
sequenced. Details about PCR reactions and sequence analysis are
reported in Supplemental methods. In the case of novel mutations,
we verified: the absence in 150 chromosomes from normocholes-
terolemic individuals of the same ethnic group; segregation of the
sequence variant in the relatives available; conservation of substi-
tuted aminoacid residues across homologous proteins by BLASTP.
2.3.2. Multiplex ligation-dependent probe analysis
We used multiplex ligation-dependent probe amplification
(MLPA) to identify large rearrangements in the LDLR gene as
described in Supplemental methods.
2.3.3. cDNA/RNA analysis
To identify splicing mutations, we performed RT-PCR analysis
as described in Supplemental methods.
2.4. Mononuclear cell isolation and generation of Epstein-Barr
Virus (EBV)-transformed cell lines
For each patient or control subject, peripheral blood mononu-
clear cells (PBMCs) were isolated from a blood sample as described
in Supplemental methods. EBV-transformed cell lines were gen-
erated exposing PBMCs to free EBV particles, produced by an
EBV-infected marmoset cell line (B95.8).
2.5. LDL uptake assay by fluorescent-activated cell sorter (FACS)
flow cytometry
Residual LDLR activity was evaluated bymeasuring binding and
uptake of a fluorescently labelled LDL as reported in Supplemental
methods. Four samples from healthy subjects were used as refer-
ence.
Fluorescence intensitiesweremeasuredwith a FACSCanto (Bec-
ton Dickinson) flow cytometer according to the manufacturer’s
instructions. The results are expressed as the ratio between the
median fluorescence intensity of cells from FH patients and the
meanof themedianfluorescence intensityof control cells. This ratio
represents residual LDLR activity. Allmeasurements havebeenper-
formed in duplicate.
2.6. Statistical analysis
Statistical analyseswere carried outwith the Statistical Package
for the Social Sciences version 16.0 (SPSS Inc., Chicago, IL, USA) as
described in Supplemental methods.
3. Results
3.1. Mutation screening of the LDLR gene
We screened 56 unrelated FH patients from Southern Italy for
mutations in the LDLR gene, and identified 16 known and 5 novel
mutations in 43 subjects (Table 1). Direct sequencing of the pro-
moter and encoding regions of the LDLR gene revealed mutations Ta
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Table 2
Measurement of residual LDLR activity by fluorescent-activated cell sorter (FACS)
flow cytometry.
Sample Median of
fluorescence
intensity
Residual activity of
LDLR
Controls 1436a 100%
p.Ser123Pro and p.Ser493CysfsX42 459 32%
p.Asp136Val 1097 76%
p.Asp136Val and p.Gly592Glu 516 36%
p.Gly592Glu 1284 89%
p.Ser142ArgfsX62 683 49%
p.Ala771 796del 743 52%
a For controls the mean of median values of four samples were considered (stan-
dard deviation is 205).
in 40/56 patients (mutation rate 71.4%). In the 16 patients with-
out detectable mutations at sequence analysis, we carried out an
MLPA analysis to search for large rearrangements and found gross
deletions in 3/16 subjects. Using these two methods, we identified
mutations in 43/56 subjects (mutation rate, 76.8%).
The 5 new mutations were absent in 150 chromosomes
from normal individuals. Three new mutations are a single
nucleotide change (c.367T>C; c.407A>T; c.1295T>C) result-
ing in an aminoacid substitution (p.Ser123Pro; p.Asp136Val;
p.Leu432Pro). The last two variations affect aminoacid residues
conserved across the homologous LDL receptor proteins from
12 different examined species. Differently, p.Ser123Pro is con-
served only in 7/12 species (chimpanzee, gorilla, orangutan, cat,
rat, mouse and guinea pig) and it is not conserved in macaque,
dog, pig, cowand zebrafish. Variation c.424 430delTCCTGCC causes
a frameshift that resulted in the formation of a premature
stop codon (p.Ser142ArgfsX62). Lastly, we identified a dele-
tion/insertion mutation of two base pairs (c.116 117delGCinsAA)
that gives rise to a premature stop codon producing a truncated
protein of 38 aminoacids (p.Cys39X) that lacks most of the LDLR
domains. Variants c.367T>C, c.407A>T, c.424 430delTCCTGCC and
c.116 117delGCinsAA segregated with the FH phenotype, whereas
c.1295T>C occurred in a single FH subject.
3.2. Functional characterization of LDLR
Todetermine the functional activityof theLDL receptor,weeval-
uated binding and uptake of fluorescent LDL (DiI-LDL) followed by
FACS analysis.
Mutation c.367T>C (p.Ser123Pro) was identified in a com-
pound heterozygote that also bears mutation c.1478 1479delCT
(p.Ser493CysfsX42),whichhasalreadybeen identified [7] andchar-
acterized [4]. In this patient, the residual LDLR activity was about
32% compared to the normal controls (Table 2).
The residual LDLR activity in a cell line carrying mutation
c.407A>T (p.Asp136Val) in heterozygosis was 76% (Table 2).
During our screening, we found a member of the same family
that was a compound heterozygote for both mutation c.407A>T
(p.Asp136Val) and mutation c.1775G>A (p.Gly592Glu). In this
compound heterozygote, the residual LDLR activity was 36%
(Table 2). The residual LDLR activity in a patient carrying mutation
c.1775G>A (p.Gly592Glu) in heterozygosis was 89% (Table 2).
Mutation c.424 430delTCCTGCC (p.Ser142ArgfsX62) was found
in heterozygosis in 3 members of the same family. The residual
LDLR activity evaluated in a cell line bearing this mutationwas 49%
(Table 2).
Finally, we carried out a functional characterization of the
knownmutation c.2312-3C>A that disrupts the donor splice site of
intron 15 and results in a transcript that has an in-frame skipping
of exon 16, as revealed by RT-PCR. The resulting protein has a dele-
tion of a portion of the transmembrane domain (p.Ala771 796del).
We measured the residual LDLR activity in 3 FH patients carrying
c.2312-3C>A and obtained a mean value of 52% (range 50–53%)
compared to normal controls (Table 2).
4. Discussion
In the attempt to enlarge the genetic spectrum of FH-causative
mutations in the LDLR gene,we screened 56unrelated subjects that
had a clinical diagnosis of FH, and we found 5 novel mutations.
Regarding mutation c.367T>C (p.Ser123Pro), a variant
(p.Ser123Thr) has previously been described in the same position
[14] although this aminoacid residue is conserved only in homo-
logue protein from 7/12 species. We characterized this mutation
in a compound heterozygote for c.367T>C and c.1478 1479delCT
(p.Ser493CysfsX42), and obtained a residual LDLR activity of
32%. This result indicates that, even if the patient carries the
c.1478 1479delCT variant, which is more likely to induce the com-
plete allele loss, mutation c.367T>C (p.Ser123Pro) is responsible
for an additional decrease in the LDLR activity.
In our study, mutation c.407A>T (p.Asp136Val) was found
alone and in compound heterozygosis together with c.1775G>A
(p.Gly592Glu). Mutations c.407A>T and c.1775G>A had, in het-
erozygosis, a residual LDLRactivity of 76%and89% respectively. The
presence of both mutations in a compound heterozygote resulted
in residual LDLR activity of 36%. This seems to suggest that if a sin-
glemutation causes an appropriate compensatory increase of LDLR
transcription, the compensatory increase of LDLR transcription in
the presence of two mutated alleles is ineffective. The mutation
c.1295T>C (p.Leu432Pro) occurs at the same codon as that previ-
ously described for the c.1294C>G (p.Leu432Val) mutation and it
affects a highly conserved aminoacid located in the EGF precursor
homologous domain [15].
Regardingmutation c.424 430delTCCTGCC (p.Ser142ArgfsX62),
the residual LDLR activity was 49% indicating that the mutated
allele has no functional activity.
Although we did not functionally characterize mutation
c.116 117delGCinsAA (p.Cys39X), it might cause FH because it
encodes a protein of only 38 aminoacids that probably has no func-
tional activity for the mutated allele.
Despite the high genetic heterogeneity of FH-causing LDLR
mutations, generally associated with a low frequency rate, in our
population the c.2312-3C>A (p.Ala771 796del) variant accounts
for20%of allmutation cases. Thesedata agreewithprevious reports
and suggest thismutation has a founder effect in our region [6]. The
mean residual LDLR activity of the c.2312-3C>Amutationwas 52%,
which implies that this mutation causes the complete functional
lossof theproteinencodedby themutatedallele.MLPAscreening in
our subjects without mutations at sequence analysis increased the
mutation rate from71.4% to 76.8%. This result supports the concept
that genetic screening in FH disease should include the detection
of large rearrangements.
In conclusion, our identificationof 5novelmutations in the LDLR
gene enlarges the genetic heterogeneity of FH disease in our region
and demonstrates the causative role of these mutations.
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 Supplementary key words LDL receptor • familial hypercholester-
olemia • EBV-transformed B-lymphocytes • mitogen stimulated T-lym-
phocytes • functional activity 
 Familial hypercholesterolemia (FH) is an autosomal 
dominant disorder characterized by elevated plasma LDL 
cholesterol, tendon xanthomas, and premature coronary 
heart disease. FH is mostly caused by mutations within the 
low density lipoprotein receptor (LDLR; MIM# 143890) 
gene, or in its ligand apoB-100 (MIM# 107730), or in the 
proprotein convertase subtilisin/kexin type 9 (PCSK9; 
MIM# 607786) gene ( 1 ). 
 At present, more than 1,100 variants of LDLR gene have 
been listed in the LDLR databases underlying a high ge-
netic heterogeneity of LDLR mutations. These are distrib-
uted across the 18 exons, introns, and the promoter region 
of the LDLR gene and include point mutations, insertions, 
deletions, and major rearrangements ( 2 ). 
 Although LDLR defects are primarily identifi ed by ge-
netic methods, it is extremely important to demonstrate a 
defi ciency in the LDLR function of FH suspect patients 
through functional studies. Receptor assays reported so 
far include measurement of radiolabeled-LDL or fl uores-
cently-labeled LDL binding and/or uptake in skin fi broblasts 
 Abstract  The main causes of familial hypercholesterolemia 
(FH) are mutations in LDL receptor (LDLR) gene. Func-
tional studies are necessary to demonstrate the LDLR func-
tion impairment caused by mutations and would be useful 
as a diagnostic tool if they allow discrimination between FH 
patients and controls. In order to identify the best method 
to detect LDLR activity, we compared continuous Epstein-
Barr virus (EBV)-transformed B-lymphocytes and mitogen 
stimulated T-lymphocytes. In addition, we characterized 
both novel and known mutations in the LDLR gene. T-lym-
phocytes and EBV-transformed B-lymphocytes were ob-
tained from peripheral blood of 24 FH patients and 24 
control subjects. Functional assays were performed by incu-
bation with fl uorescent LDL followed by fl ow cytometry 
analysis. Residual LDLR activity was calculated normalizing 
fl uorescence for the mean fl uorescence of controls. With 
stimulated T-lymphocytes we obtained a better discrimina-
tion capacity between controls and FH patients compared 
with EBV-transformed B-lymphocytes as demonstrated 
by receiver operating characteristic (ROC) curve analysis 
(the areas under the curve are 1.000 and 0.984 respectively; 
 P < 0.0001 both).  The characterization of LDLR activity 
through T-lymphocytes is more simple and faster than the 
use of EBV-transformed B-lymphocytes and allows a com-
plete discrimination between controls and FH patients. 
Therefore the evaluation of residual LDLR activity could be 
helpful not only for mutation characterization but also for 
diagnostic purposes. —Romano,M., M. Donata Di Taranto, 
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FBS (Lonza) and 10% DMSO in liquid nitrogen until required 
for use. 
 EBV-transformed cell lines were generated by exposing 
PBMCs to free EBV particles, produced by an EBV-infected mar-
moset cell line (B95.8). After EBV infection, transformed PBMCs 
were cultured in an incubator at 37°C in a 5% CO 2 atmosphere 
in Iscove’s Modifi ed Dulbecco’s Medium (IMDM, Sigma-Aldrich) 
supplemented with 20% FBS and 2% Ultraglutamine (Lonza). 
The continuous cell lines bearing the LDLR mutations were also 
analyzed to verify the presence of DNA variations. In order to 
upregulate LDLR, the cells were incubated in a medium contain-
ing a lipoprotein deprived serum (LPDS, Sigma-Aldrich) for 48 h 
before being analyzed. 
 Peripheral blood T-lymphocytes stimulation 
 After two wash steps in FBS, thawed PBMC were counted and 
seeded in a 24-well plate (BD-Falcon) at 1 × 10 6 cells/ml in 
IMDM supplemented with 10% human LPDS to induce LDLR 
upregulation and 2% Ultraglutamine. Stimulation of T-lympho-
cytes was carried out for 48 h at 37°C and 5% CO 2 with three 
different combinations of mitogens:  1 ) 5 m g/ml phytohemagglu-
tinin (PHA) (Sigma-Aldrich),  2 ) PHA and 10 ng/ml phorbol 
12-myristate 13-acetate (PMA, Sigma-Aldrich), and  3 ) 1  m M ion-
omycin (Sigma-Aldrich) and 10 ng/ml PMA according to Makar 
et al. ( 12 ). 
 LDL uptake assay by fl uorescent-activated cell sorter 
fl ow cytometry 
 Residual LDLR activity was evaluated by measuring the 
binding and uptake of a fl uorescently labeled LDL, namely 
1,19-dioctadecyl-3,3,3 ′ ,3 ′ -tetramethylindocarbocyanine perchlo-
rate-conjugated LDL (DiI-LDL, Invitrogen), in EBV-transformed 
B lymphocytes and mitogen-stimulated T-lymphocytes. Briefl y, 
cells were collected and diluted at 1 × 10 6 cells/ml in DMEM:F12 
(Sigma-Aldrich) without phenol red and LPDS. Two aliquots of 
cells for each sample analyzed were then incubated for 3 h at 
37°C and 5% CO 2 as follows:  a ) with 30 mg/L unlabeled LDL 
(Sigma-Aldrich), to measure background fl uorescence; and  b ) 
with 10 mg/L DiI-LDL to estimate the maximum LDL binding 
and uptake. In preliminary experiments we performed an addi-
tional incubation with 30 mg/L unlabeled LDL plus 10 mg/L 
DiI-LDL (ratio 3:1) to evaluate the displacement of DiI-LDL and 
in this condition, we observed a reduction of cell fl uorescence 
indicating the specifi c binding of DiI-LDL (supplementary  Fig. I ). 
After three washes in with PBS without Ca 2+ and Mg 2+ , fl uores-
cence intensities were measured with a FACSCanto (Becton-
Dickinson) fl ow cytometer according to the manufacturer’s 
instructions. Forward scatter and side scatter gates were estab-
lished to exclude dead cells and cell debris. An example of fl ow 
cytometry gating is shown in supplementary  Fig. II that also shows 
the percentage of CD3 + cells (T-lymphocytes) obtained with the 
ionomycin plus PMA stimulation. For each experiment, 10,000 
events were counted. 
 The results are expressed as the median of fl uorescence and as 
the ratio between the median fl uorescence intensity of cells from 
FH patients and the mean of the median fl uorescence intensity 
of control cells. This ratio represents residual LDLR activity. All 
measurements were performed in duplicate. 
 Statistical analysis 
 The normality of variable distributions was evaluated with Kol-
mogorov-Smirnov test. Continuous variables were indicated as 
mean ± SD. Differences between the continuous variables were 
evaluated with  t -test. A value of  P < 0.05 was considered statisti-
cally signifi cant. Statistical analyses were carried out using the 
( 3, 4 ) or leukocytes ( 5, 6 ). The Epstein-Barr virus (EBV)-
transformed B-lymphocytes show high LDLR levels and al-
low an unlimited supply of cells without being infl uenced 
by the patient’s diet and drug treatment ( 7 ). The main 
problem of these functional assays was the bad separation 
between residual LDLR activity from FH patients and con-
trols. The separation of different leukocyte populations 
obtains more accurate results ( 8 ); the selection of viable 
lymphocytes by stimulation with a mitogen or by fl ow 
cytometry gating improves the discrimination between pa-
tients and controls although it does not allow complete 
discrimination of FH heterozygote patients from healthy 
controls ( 9, 10 ). 
 The aim of this study was to improve the method of 
T-lymphocyte stimulation for LDLR activity evaluation 
through the comparison of different mitogen combina-
tions. We also aimed to compare continuous EBV-trans-
formed-lymphocytes and mitogen stimulated T- lymphocytes 
obtained from peripheral blood samples in order to iden-
tify the best method to detect LDLR activity by fl uores-
cently-labeled LDL. In addition, we characterized both 
novel and known mutations in the LDLR gene. 
 MATERIALS AND METHODS 
 FH patients and control subjects 
 Patients with clinically diagnosed FH were enrolled at the Di-
partimento di Medicina Clinica e Sperimentale, Università degli 
Studi di Napoli Federico II and at the AORN Cardarelli, Napoli. 
The FH diagnosis was based on the criteria established by the 
Società Italiana per lo Studio della Arteriosclerosi for the identi-
fi cation and treatment of dyslipidemias. Twenty-four patients 
bearing new and known mutations were selected for functional 
characterization. As healthy controls, 24 unrelated subjects were 
selected from voluntary donors of the Centro Trasfusionale of 
the AORN Cardarelli, Napoli, on the basis of normal lipid levels 
and absence of LDLR mutations. The supplementary table re-
ports characteristics of FH patients and controls. The study was 
performed according to the current version of the Helsinki Dec-
laration. Informed consent was obtained for each patient. 
 Mutation screening 
 Molecular analysis for the identifi cation of LDLR mutations 
was performed as previously described ( 11 ). Briefl y, the pro-
moter and the 18 exons of the LDLR gene were amplifi ed by PCR 
and directly sequenced. In the case of novel mutations, we veri-
fi ed the absence in 150 chromosomes from normocholester-
olemic individuals of the same ethnic group, the segregation of 
the sequence variant in the relatives available, and the conserva-
tion of substituted amino acid residues across homologous pro-
teins by BLASTP. 
 Mononuclear cell isolation and generation 
of EBV-transformed B-lymphocytes 
 Peripheral blood mononuclear cells (PBMCs) were isolated 
from 9 ml of EDTA blood collected from each subject enrolled in 
this study. The sample was diluted 1 in 2 with PBS without Ca 2+ 
and Mg 2+ pH 7.4, and then layered on Ficoll-Paque (Lymphocyte 
Separation Medium, MP Biomedicals). After centrifugation 
at 1,500 rpm for 30 min at 4°C, mononuclear cells were recov-
ered at interface, washed three times in PBS and stored in 90% 
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87.3%, respectively. As regards LDL-R expression evaluated 
by the uptake of DiI-LDL, in case of PHA stimulation, the 
uptake of DiI-LDL was lower than that observed with PHA 
plus PMA and ionomycin plus PMA (supplementary Fig. I). 
Due to the higher yield of live T-lymphocytes obtained with 
ionomycin plus PMA with respect to PHA plus PMA and 
considering the LDLR upregulation in T-lymphocytes de-
scribed by Makar et al. ( 12 ) using ionomycin plus PMA, we 
selected this method for further experiments. 
 Functional characterization of LDLR activity 
 The median of fl uorescence intensity and the residual 
LDLR activity evaluated in EBV-transformed B-lympho-
cytes and in ionomycin plus PMA stimulated T-lympho-
cytes from healthy subjects with normal lipid profi le and 
no mutations in LDLR are reported in  Table 1 . A repre-
sentative set of data from fl ow cytometry analysis is shown 
in supplementary Fig. III. The residual LDLR activity was 
calculated using the mean of median values of all analyzed 
controls as areference (1,752 for EBV-transformed B-lym-
phocytes and 1,011 for stimulated T-lymphocytes). As for 
controls, this calculation represents a data normalization 
allowing the comparison between the two methods used. 
The minimum and maximum values of residual LDLR ac-
tivity evaluated on EBV-transformed B-lymphocytes from 
controls were 71% and 132%, respectively, whereas the 
minimum and maximum values of residual LDLR activity 
evaluated on stimulated T-lymphocytes were 79% and 
133%, respectively. The median of fl uorescence intensity 
and the residual LDLR activity in EBV-transformed B-lym-
phocytes and in stimulated T-lymphocytes from FH pa-
tients with mutations in LDLR gene are reported in  Table 2 . 
 The residual LDLR activities were statistically different be-
tween control subjects and FH patients analyzed by both 
methodologies ( P < 0.0001 both). Regarding the func-
tional characterization of new mutations, we observed low 
residual LDLR activities consistent with a heterozygous sta-
tus of FH ( Table 2 ). 
 Figure 1  shows a graphical representation of residual 
LDLR activity of each control and FH patient evaluated by 
the two methods. We observed that, using EBV-transformed 
B-lymphocytes, there is an overlap of residual LDLR activi-
ties between controls and patients in the range 71–75%, 
whereas, using stimulated T-lymphocytes, no value in the 
range 65–79% was observed for controls nor for FH pa-
tients. The use of stimulated T-lymphocytes allows a com-
plete discrimination between controls and FH patients. 
 Analysis of ROC curves 
 The ROC curves are constructed using the residual 
LDLR activity evaluated in EBV-transformed B-lympho-
cytes and in stimulated T-lymphocytes as a discriminator 
parameter between FH patients and healthy controls ( Fig. 2 ). 
 The AUC of the methods based on EBV-transformed 
B-lymphocytes and on stimulated T-lymphocytes are 0.984 
[95% confi dence interval (CI) 0.880–1.000] and 1.000 
(95% CI 0.907–1.000), respectively ( P < 0.0001 both). The 
comparison of the AUC of the two methods does not re-
veal any statistically signifi cant difference ( P = 0.41). 
statistical Predictive Analytics Software version 18.0 (SPSS Inc.). 
Analysis of receiver operating characteristic (ROC) curves and 
dot diagrams was performed with MedCalc Version 11.5.1. The 
statistical signifi cance of the area under the ROC curves (AUC) 
was calculated against the null hypothesis AUC = 0.5 as recom-
mended by DeLong et al. ( 13 ). The threshold values were deter-
mined by the farthest point from the bisector of the ROC curve. 
 RESULTS 
 Mutation screening 
 We identifi ed four new mutations absent in 150 chro-
mosomes from normal individuals ( Table 1 ). These altera-
tions are novel missense mutations (c.440C>T; c.974G>A; 
c.1130G>T; c.1739C>T) that result in a single amino acid 
substitution in LDL receptor protein (p.Thr147Ile; 
p.Cys325Tyr; p.Cys377Phe; p.Ser580Phe). The novel mu-
tations cause changes of amino acid residues conserved 
across fourteen species examined during our study. 
 T-lymphocytes mitogen selection 
 In order to select the best way to stimulate T-lympho-
cytes able to express LDLR, we compared three known 
procedures for in vitro growth stimulation of T-cells. The 
fl ow cytometry analysis showed that the amount of viable 
T-lymphocytes in cells treated with  1 ) PHA,  2 ) PHA plus 
PMA, and  3 ) ionomycin plus PMA was 76.4%, 83.8%, and 
 TABLE 1. Medians of fl uorescent intensity and LDLR residual 
activities evaluated on EBV-transformed B-lymphocytes and stimulated 
T-lymphocytes from control subjects. 
Control ID
Median of 
fl uorescent 
intensity 
on EBV-
transformed 
B-lymphocytes
Median of 
fl uorescent 
intensity on 
stimulated 
T-lymphocytes
LDLR residual 
activity on EBV-
transformed 
B-lymphocytes
LDLR residual 
activity on 
stimulated 
T-lymphocytes
Control 1 2,173 1,132 124.0 111.9
Control 2 1,654 1,161 94.4 114.8
Control 3 1,754 1,349 100.1 133.4
Control 4 2,304 931 131.5 92.0
Control 5 1,981 1,106 113.0 109.3
Control 6 2,150 928 122.7 91.7
Control 7 2,103 1,103 120.0 109.0
Control 8 1,524 948 86.9 93.7
Control 9 1,289 869 73.5 85.9
Control 10 2,056 952 117.3 94.1
Control 11 1,924 904 109.8 89.4
Control 12 1,257 799 71.7 79.0
Control 13 1,582 – 90.2 –
Control 14 1,387 – 79.1 –
Control 15 1,238 – 70.6 –
Control 16 1,658 – 94.6 –
Control 17 – 1,048 – 103.6
Control 18 – 963 – 95.2
Control 19 – 905 – 89.5
Control 20 – 1,231 – 121.7
Control 21 – 1,101 – 108.9
Control 22 – 940 – 92.9
Control 23 – 882 – 87.2
Control 24 – 960 – 94.9
Mean ± SD 1,752 ± 355 1,011 ± 138 100.0 ± 20.3 100.0 ± 13.6
CV% 20.3 13.6 20.3 13.6
Missing data are relative to unavailable samples. CV%, coeffi cient 
of variation.
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because in our experimental conditions, it gives the best 
results. In other studies, functional assays were conducted 
on T-lymphocytes using only PHA ( 21, 22 ) although the 
comparison between different mitogens was not per-
formed. For the fi rst time, we compared two cell culture 
techniques useful in detecting residual LDLR activity in 
FH patients: EBV-transformed B-lymphocytes and mitogen 
stimulated T-lymphocytes both treated with fl uorescently-
labeled LDL. In controls, we observed a higher median of 
fl uorescent intensity in EBV-transformed B-lymphocytes 
than in stimulated T-lymphocytes, suggesting the highest 
LDLR expression in the fi rst cell type. The residual LDLR 
activity evaluated on stimulated T-lymphocytes of controls 
shows a more limited range of values, suggesting a minor 
LDLR expression variability. 
 The minimum value of residual LDLR activity in con-
trols is higher for stimulated T-lymphocytes than for EBV-
transformed B-lymphocytes (79% and 71%, respectively) 
suggesting that the T-lymphocytes based method has a bet-
ter capacity to detect functional activity than the other 
one. With ionomycin plus PMA stimulated T-lymphocytes, 
no value was observed in the range 65–79% (discriminat-
ing range) for controls nor for FH patients, whereas using 
EBV-transformed B-lymphocytes, we observed an overlap in 
residual LDLR activities between controls and patients in the 
range 71–75% (absence of a discriminating range). Then, 
using stimulated T-lymphocytes, we obtained a complete dis-
crimination between FH patients and normocholesterolemic 
 By the analysis of ROC curves, the suggested threshold 
of residual LDLR activity for discrimination between con-
trols and patients is 67.7% for EBV-transformed B-lympho-
cytes (86.96% sensitivity and 100% specifi city) and 64.6% 
for stimulated T-lymphocytes (100% sensitivity and 100% 
specifi city). 
 DISCUSSION 
 The functional characterization of LDLR mutations by 
use of EBV-transformed B-lymphocytes provides the ad-
vantages of continuous cell lines that undergo rapid prolif-
eration combined with a long lifespan. These are easily 
reestablished in culture after being frozen and are useful 
in the creation of cell banks for future molecular studies. 
These advantages enable a reliable characterization of 
novel and known mutations in LDLR gene and other ge-
netic disorders ( 20 ). However, EBV-transformed B-lym-
phocytes must be used carefully because of decreased 
genetic stability and possible changes in cellular processes 
induced by viral transformation ( 20 ). The generation of 
EBV-transformed B-lymphocytes is wasteful, time-consum-
ing, and often results tare unproductive depending on the 
quantity of leukocytes isolated from each subject. 
 In order to overcome these problems, we have improved 
an assay to evaluate LDLR activity in peripheral-blood lym-
phocytes using ionomycin plus PMA-induced proliferat-
ing T-lymphocytes. We selected this mitogen combination 
 TABLE 2. Medians of fl uorescent intensity and residual LDLR activities evaluated on EBV-transformed 
B-lymphocytes and stimulated T-lymphocytes from FH patients 
Nucleotide change Effect on protein Reference Status
Median of 
fl uorescent 
intensity on EBV-
transformed 
B-lymphocytes
Median of 
fl uorescent 
intensity on 
stimulated 
T-lymphocytes
LDLR residual 
activity on EBV-
transformed 
B-lymphocytes
LDLR residual 
activity on 
stimulated 
T-lymphocytes
c.116_117
delGCinsAA
p.Cys39X 11 heterozygote 1,113 444 63.5 43.9
c.367T>C and 
c.1478_1479delCT
p.Ser123Pro and 
p.Ser493CysfsX42
11 and 14 compound 
heterozygote
459 – 26.1 –
c.407A>T p.Asp136Val 11 heterozygote 1,097 – 62.6 –
c.407A>T and 
c.1775G>A
p.Asp136Val and 
p.Gly592Glu
11 and 15 compound 
heterozygote
516 220 29.4 21.7
c.424_430
delTCCTGCC
p.Ser142ArgfsX62 11 heterozygote 1,186 647 67.6 64.0
c.440C>T p.Thr147Ile new heterozygote 982 – 56.0 –
c.440C>T p.Thr147Ile new heterozygote 1,241 562 70.8 55.6
c.974G>A p.Cys325Tyr new heterozygote 949 572 54.1 56.6
c.1130G>T p.Cys377Phe new heterozygote 750 – 42.8 –
c.1135T>C p.Cys379Arg 15 heterozygote 1,157 566 66.0 56.0
c.1187-10G>A p.Gly396AspfsX19 16 heterozygote 944 – 53.8 –
c.1187-10G>A p.Gly396AspfsX19 16 heterozygote 1,317 615 75.1 60.8
c.1567G>A p.Val523Met 17 heterozygote 635 607 36.2 60.0
c.1646G>A p.Gly549Asp 18 heterozygote 979 354 55.8 35.0
c.1646G>A p.Gly549Asp 18 heterozygote 831 653 47.4 64.6
c.1646G>A p.Gly549Asp 18 heterozygote 1,149 503 65.5 49.7
c.1739C>T p.Ser580Phe new heterozygote 1,152 646 65.7 63.9
c.1739C>T and 
c.1646G>A
p.Ser580Phe and 
p.Gly549Asp
new and 18 compound 
heterozygote
741 306 42.2 30.2
c.1775G>A p.Gly592Glu 15 heterozygote 1,284 – 73.2 –
c.1775G>A p.Gly592Glu 15 homozygote 682 537 38.9 53.1
c.1846-?_2311+?del p.Asp616LeufsX17 17 heterozygote 338 367 19.2 36.3
c.2312-3C>A p.Ala771_796del 19 heterozygote 724 567 41.3 56.1
c.2312-3C>A p.Ala771_796del 19 heterozygote 763 478 43.5 47.2
c.2312-3C>A p.Ala771_796del 19 heterozygote – 653 – 64.6
Missing data are relative to unavailable samples.
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simple and fast and improves the detection of LDL recep-
tor activity defects, allowing complete discrimination 
between controls and FH patients. Furthermore, the 
evaluation of residual LDLR activity could be helpful not 
only for mutation characterization but also for diagnostic 
purposes.  
 The authors gratefully acknowledge the contribution of the 
Biobank of CEINGE for isolation of peripheral blood mononuclear 
cells and generation of EBV-transformed cell lines. 
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Abstract. Single nucleotide polymorphisms (SNPs) are the foremost
part of many genome association studies. Selecting a subset of SNPs that
is sufficiently informative but still small enough to reduce the genotyping
overhead is an important step towards disease-gene association. In this
work, a Random Forest (RF) approach to informative SNPs selection
in Familial Combined Hyperlipidemia (FCH) is proposed. FCH is the
most common form of familial hyperlipidemia. Affected patients have
elevated levels of plasma triglycerides and/or total cholesterol and show
increased risk of premature coronary heart disease. In order to identify
susceptibility markers for FCH we perform the analysis of 21 SNPs in
ten genes associated with high cardiovascular risk. RF appears to be a
useful technique in identifying gene polymorphisms involved in FCH: the
identified SNPs confirmed some variants in a couple of genes as genetic
markers of FCH as proved in various studies in scientific literature and
lead us to report for the first time a further gene association with FCH.
This result could be promising and encourages to further investigate on
the role of the identified gene in the development of FCH phenotype.
Keywords: Machine learning, feature selection, random forests, genome
association, single nucleotide polymorphisms, familial combined hyper-
lipidemia
1 Introduction
Genome and genome-wide association studies (GA) have revolutionized genetics
making it possible the search for genetic factors that influence common complex
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traits and the characterization of the effects of those factors [5]. Single nucleotide
polymorphisms (SNPs) are at the forefront of many disease-gene association
studies. SNPs are mutations at a single nucleotide position that occurred dur-
ing evolution and were passed on through heredity, accounting for most of the
genetic variation among different individuals. The number of SNPs has been esti-
mated to be around seven million in the human genome [8]. Thus, in GA studies,
selecting a subset of SNPs that is sufficiently informative but still small enough
to reduce the genotyping overhead is an important step towards disease-gene
associations [15]. Machine learning techniques [1] have been applied with ever
growing interest and success in GA for feature selection purposes. The success
is mostly due to their natural suitability in assessing many loci jointly which
may be more informative than testing associations at individual markers and
to deal with large amount of data. In fact, most of the studies, in this context,
have used a single-locus analysis strategy, in which each variant is tested indi-
vidually for association with a specific phenotype. However, as often stated in
literature, a reason for the lack of success in genetic studies of complex disease is
the existence of interactions between loci. If a genetic factor functions primarily
through a complex mechanism that involves multiple other genes and, possibly,
environmental factors, the effect might be missed if the gene is examined in iso-
lation without allowing for its potential interactions with these other unknown
factors [5]. A huge amount of diverse approaches have been developed in the
last decade to informative SNPs selection (see [5], [15]) and references therein
for an overview) for different disease-gene associations, ranging from multiple
sclerosis [3] to chick mortality [11]. Nonetheless, the complexity of GA studies
and the peculiarity of each disease-gene association make it impossible to figure
out the “best” technique for each application. Random Forest [2], an ensemble of
a machine learning techniques based on Decision Trees (DTs), is one candidate
model to informative SNP selection. DT [6], is a very popular technique in the
machine learning community. DT is efficient from a computational point of view,
works well with both categorical or continuous data, copes fine with missing val-
ues thanks to the notion of surrogate variables, and its resulting structure after
training is easily interpretable even for an user with no machine learning back-
ground. On the other hand, DT suffers from high variance. Often a small change
in the data can result in a very different tree structure, making interpretation
somewhat arbitrary. This motivates the use of RF, which grows a set of many
DTs and combines their results through bagging [6] resulting in a very effective
reduction of variance in each tree in the ensemble. Aim of this work is a RF infor-
mative SNPs selection in Familial Combined Hyperlipidemia (FCH) [12]. FCH is
the most common form of familial hyperlipidemia [9]. Affected patients have el-
evated levels of plasma triglycerides and/or total cholesterol and show increased
risk of premature coronary heart disease [13]. In order to identify susceptibility
markers for FCH we perform the analysis of 21 SNPs in 10 genes associated
with high cardiovascular risk: Lipoprotein Lipase (LPL), Cholesteryl ester trans-
fer protein (CETP), HMG-CoA reductase (HMGCR), PCSK9, ApoA5, ApoC3,
Upstream transcription factor 1 (USF1), Peroxisome proliferator-activated recep-
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tor gamma (PPARG), Gap junction alpha-4 (GJA4) and Kinesin-like protein 6
(KIF6).
The rest of the paper is organized as follows: Section 2 describes the fundamentals
of RF, while Section 3 illustrates the FCH sample data used, the experimental
settings and the obtained results, respectively. Finally, conclusions in Section 4
close the paper.
2 Random Forests
The RF technique is an ensemble learning technique for conducting classifica-
tion (or regression) analyses. It constructs a collection of classification trees
to aggregate them into one robust classifier. The approach is based on CART
(Classification and Regression Trees)[10]. Trees are constructed using rules that
determine how well a split at a node (based on the values of a predictor vari-
able) can differentiate observations with respect to the outcome variable. In the
following we give an overview of CART principles and motivate the need of an
ensemble of CARTs, i.e. the RF in order to better characterize the complexity
of our data.
2.1 Classification and Regression Trees
A classification problem consists of a training sample of n observations on a
class variable Y assuming values 1, 2, . . . , k, and l predictor variables, X1, ..., Xl.
The goal is to find a model for predicting the values of Y from new X values.
The most classification tree construction algorithms employ a top-down heuristic
search using recursive partitioning of data sample space. Starting from a het-
erogeneous set in terms of the variation in the outcome variable class label (i.e.,
case or control) of training samples at root node, each predictor (i.e., a SNP) is
evaluated using a statistic to determine how well it classifies the training samples
by itself. The best feature is selected to split the training samples to descendant
nodes. The whole process is recursively repeated to split the descendant nodes
until some pre-specified stopping criteria are met (for example, when all termi-
nal nodes contain only cases or only controls, or when all possible SNPs have
been included in a branch). The critical step in tree growing is to select the
best predictor (or feature in the machine learning jargon) to split a node [4].
Most algorithms evaluate the performance of a candidate feature in separating
different class labels in the training samples. The concept of impurity is usually
used. Here we consider the Gini index as measure of impurity within node t:
IG(t) =
k∑
i=1
pi(t)(1− pi(t)),
where p1, p2, . . . , pk are the proportion of samples in the k classes. Then, in
binary trees, a feature and a split are chosen according to the following decrement
in impurity:
∆(s, t) = I(t)− h(tL)I(tL)− h(tR)I(tR)
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where s is a split of node t, h(tL) and h(tR) are the proportions of the samples
in the left and right child nodes of node t, respectively. By recursively using
the node-splitting procedure, one usually ends up with an overgrown tree (with
too many descendant nodes), which produces a tree that overfits the training
samples and is prone to random variations in the data. Two commonly employed
strategies to overcome the overfitting are to interrupt the tree growing by a stop-
splitting criterion and to apply a pruning step on the overgrown tree. The stop-
splitting criterion could be either based on the node size, the node homogeneity,
or elaborate criterion based on statistical testing.
2.2 Ensemble of trees
Although tree models are easy to interpret, single tree-based analysis has its own
limitations in analyzing datasets:
– The topology of a tree is usually unstable. A minor perturbation of the input
training sample could result in a totally different tree model. The major
reason for this instability is the hierarchical nature of the process: the effect
of an error in the top split is propagated down to all of the splits below it.
– For high dimensional data a single parsimonious model is not enough to
reflect the complexity in the dataset.
– A single tree may have a relatively lower accuracy in prediction with respect
to other machine learning approach (e.g., Support Vector Machine (SVM)
or Neural Networks (NN) [1]).
Furthermore, when one faces with small sample sizes, their inherent risk of im-
precision and overfitting is higher with single tree models. Rather than using a
single classification tree, an high increase in prediction accuracy can result from
growing an ensemble of trees and letting them “vote” for the most popular out-
come class, given a set of input variable values. This way the ensemble adjusts
for the instability of the individual trees induced by small changes in the learn-
ing sample. Such ensemble approaches can also be used to provide measures of
variable importance. RF is the most widely used ensemble tree approach. A RF
consists of hundreds or thousands of unpruned tree each one fitted to a bootstrap
sample of the same size (for example, the same number of cases and controls)
from the original data. Although an individual tree in the forest is not a good
model by itself, the aggregated classification has been shown to achieve much
better performance than what a single tree may achieve. To construct an RF
with B trees from a training dataset with n observations (cases and controls)
with l features or predictors (SNPs), we employ the following steps:
1. A bootstrap sample is drawn from the training sample;
2. A classification tree is grown for the bootstrap sample. At each node, the
split is selected on the basis of a randomly selected subset (much smaller
than l) features. The tree is grown to full size without pruning;
3. Steps 1 and 2 are repeated B times to form a forest. The ensemble classifi-
cation label is made by a majority vote of all trees in the ensemble.
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Out-f-bag samples, classification accuracy and variable importance
The RF algorithm does not use all training samples in the construction of the in-
dividual tree, rather it leaves a set of out-of-bag (oob) samples, which can be used
to measure the forest classification accuracy [6] with no need of cross-validation
or test sets. The out-of-bag observations can also be used to estimate variable
importance by a permutation importance index, namely, to measure a specific
feature’s importance in the tree. When the b-th tree is grown (b = 1, . . . B), the
oob samples are passed down the tree, and the prediction accuracy is recorded.
The values for the j-th feature are randomly permuted in the oob samples, and
the accuracy is again computed. In this way by randomly permuting a feature
values, its original association with the outcome variable is broken. When the
permuted feature, together with the remaining unpermuted predictor variables,
is used to predict the response, the prediction accuracy (i.e., the number of ob-
servation classified correctly) decrease substantially if the original variable was
associated with the response. Thus, the larger the decrease of the prediction
accuracy, the more important the variable. This process is repeated for each
feature.
3 Experiments
To detect the genetic loci and their interactions that influence a phenotypic out-
come (case or control), the FCH data sample has been analyzed by RF which
produces, in each of its constituent tree, a graphical structure (see Fig. 1) that
resembles an upside-down tree that maps the possible values of certain predictor
variables (e.g., SNP genotypes) to a final expected outcome (e.g., disease sta-
tus). Each node of the tree represents a predictor variable and there are edges
from each node leading down to “child” nodes, in which edge correspond to a
different possible value that could be taken by the variable in the parent node.
A path through the tree represents a particular combination of values taken by
the predictor variables that are present within the path. In this way, we found
a subset of SNPs localized in different genes and their association with FCH.
We also performed classical statistical tests for the frequency comparison. Dif-
ferences between groups were assessed by χ2 test and a p-value less than 0.05
was considered significant.
3.1 The data
After genomic DNA extraction from peripheral blood samples, the TaqMan assay
was performed for the SNP typing. Real-Time PCR reactions were performed on
a ABI Prism 7900−HT instrument and subsequent data analysis were done with
the Sequence Detection System 2.3 Software (Applied Biosystem). We enrolled
123 patients with a clinical diagnosis of FCH (after exclusion of misdiagnosis
of familial hypercholesterolemia) and 142 healthy controls. Therefore, the case-
control data set is constituted by 265 observations and 21 SNPs. The homozygous
major, heterozygous, homozygous minor alleles have been coded by 1, 2, and 3,
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Fig. 1. An example of a single decision tree on case-control data.
respectively. Since our data sample contains few missing values for few SNPs
(see Fig.2), the missing genotypes were imputed as the single most likely values
on the basis of the genotype frequencies.
3.2 RF analysis
Starting from the original case-control FCH sample, RF formed by 500 to 1000
trees have been trained in order to assess the SNP importance by the permu-
tation importance measure, as Fig. 3 depicts. It is worth noting that, while in
Fig. 3 the results for a RF constituted by 1000 trees are reported, a RF with
500 trees would suffice to obtain a similar and stable results. Successively, the
RF was used jointly with a sequential backward selection procedure [1] as a
wrapper feature selection method [15]. Specifically, the sequential backward se-
lection starts from a subset of eight SNPs (determined by imposing, empirically,
a threshold at 0.1 to the permutation importance measure) and sequentially re-
moves a feature from the full candidate set until the removal of further features
increase the RF misclassification rate. The RF prediction accuracy as well as the
sequential backward selection are computed on the oob samples.
3.3 Results
The identified optimal feature subset contains 5 SNPs and lead to a RF pre-
diction accuracy of 68.68%: ApoA5 (S19W), ApoA5 (-1131 T> C), PCSK9
(25467958 T> C), GJA4 (P319S), USF1 (9996 G>A).
The sensitivity and specificity were 66.67% and 71.83%, respectively. Fig. 4 de-
picts the the oob error with respect to the number of trees of the RF and clearly
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Fig. 2. Fraction of missing values for each SNP in the case-control data set.
Fig. 3. SNP importance values from permutation importance measure.
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shows that a smaller RF size is enough to reach comparable results. Fig. 4 shows
the ROC curve obtained by the RF. We also performed standard frequency com-
parisons to confirm results and we found that genotypes of the above-mentioned
SNPs have a different frequency between FCH and controls.
Fig. 4. RF oob error vs number of trees (left) and RF ROC curve (right).
4 Conclusions
RF is an effective methodology for machine learning applications. It is widely
used in the research community both for classification and feature selection pur-
poses, due to its some nice properties such as the oob samples which can be
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exploited to assess the RF performance with no needs of a testing set or a
cross-validation procedure, and to evaluate the feature importance through the
permutation importance index. Moreover, an appealing characteristic is the re-
duced computational costs when compared to other calculus intensive machine
learning approach (such as neural networks or support vector machines). Several
works in GA literature employ RF as an analysis tool ([14], [16]). We applied a
RF analysis to identify a set of SNPs related to Familial Combined Hyperlipi-
demia: it has been used for a first evaluation of SNP importance through the
permutation importance index and then, in conjunction with sequential back-
ward elimination, as a wrapper feature selection procedure that can identify an
optimal set on SNPs able to correctly classify 68.68% of subjects in the FCH
sample. It is worth stressing that no other employed, for comparison purposes,
machine learning approach such as NN and SVM could obtain a prediction ac-
curacy above 65% on the same feature subset. Although the analysis is limited
to twenty-one SNPs in ten genes already associated with FCH, the literature re-
ports discordant data about these associations. This motivates our work whose
aim was to test the associations with a method of analysis different from the rou-
tinely used in case-control studies to confirm the data. So doing, we confirmed
the role of the variants S19W and −1131T > C in ApoA5 gene and 9996G > A
in USF1 gene as genetic markers of FCH [9], [12], [13]. Moreover, we reported
for the first time association of GJA4 gene and its variant P319S with FCH.
Definitely, while obtained on a relative small sample size, this result could be
promising and encourages us to further investigate on the role of this gene in the
development of FCH phenotype. Indeed, FCH has polygenic and multifactorial
basis not yet completely clarified [13]. Previous linkage and association stud-
ies indicated various genes associated to altered lipid or lipoprotein phenotype,
most of them being involved in lipid metabolism [7]. Since the polygenic basis
of the FCH disease, the combined study of different genetic variations allow to
better characterize patients and to identify high-risk subjects. Obviously, the
discovery of new variants requires the use of different genetic screening such as
wide-genome scan or linkage analysis rather than the small-scale exploratory
investigation presented in this work.
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To the Editor,
Familial hypercholesterolemia (FH) is a genetically het-
erogeneous lipid disorder with a frequency of 1:300/1:500 
for heterozygotes in many populations [1]. The pathogen-
esis of FH is caused by a dysfunctional lipid metabolism 
leading to high concentrations of total and low-density 
lipoprotein (LDL) cholesterol, however, a great pheno-
typic variability is observed.
Mutations in the LDL receptor gene (LDLR) are the 
main cause of FH, whereas the apolipoprotein B (APOB) 
and proprotein convertase subtilisin/kexin type 9 (PCSK9) 
genes are involved in a lower percentage of cases [2]. 
PCSK9 regulates the LDLR expression inducing its lysoso-
mal degradation [3]. Some variants in PCSK9 increase its 
capacity to promote LDLR degradation [gain of function 
mutations (GOF)] leading to FH, whereas other mutations 
cause a decreased PCSK9 activity [loss of function (LOF)] 
[3]. The molecular diagnosis of FH implies that a new 
mutation should be deeply studied and accompanied by 
a functional characterization before one can claim its 
pathogenicity. Herein, we present the rare case of a family 
with a suspect of FH in which two members carried a new 
variant in the PCSK9 gene and two members carried a 
known variant in the APOB gene.
The proband (I.2; Figure 1) is a 68-year-old woman 
with hypercholesterolemia, hypertriglyceridemia as well 
as a clinical history of hypertension, hyperglycemia, 
carotid and peripheral atherosclerosis referred to the 
Dipartimento di Medicina Clinica e Chirurgia, Università 
degli Studi di Napoli Federico II. The study was performed 
according to the current version of the Helsinki Declara-
tion. Informed consent was obtained for each patient or 
control. The proband’s father died of a heart attack at the 
age of 64 and her mother has 7.8 mmol/L of total choles-
terol. The patient reported that she suspended previous 
therapies with atorvastatin or rosuvastatin due to the 
appearance of myalgia. Laboratory analyses in absence 
of therapy revealed an altered lipid profile as shown in 
Table 1. The proband (I.2) showed elevated serum levels 
of total cholesterol, LDL-cholesterol, triglycerides as well 
as increased apoB levels and LDL score. No sign of corneal 
arcus or tendinous xanthomata was found, leading to a 
diagnosis of possible FH according to the Simon Broome 
criteria [5]. Sequencing and MLPA analysis of the LDLR 
gene performed as previously described [6] did not reveal 
any mutation or large rearrangements in the proband. 
Sequencing of the 12 exons with flanking intron sequences 
of the PCSK9 gene showed that the proband (I.2) (Figure 1) 
was heterozygous for the new variant c.1394C > T in exon 9, 
corresponding to the amino acid substitution p.Ser465Leu.
We verified the absence of the variant in 150 chro-
mosomes from normocholesterolemic individuals. To 
evaluate the segregation of the new variant with the 
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hypercholesterolemic phenotype, the mutation was 
searched in the proband’s daughters (II.1 and II.2; Figure 1) 
aged 43 and 36 who showed elevated total cholesterol and 
LDL-cholesterol levels only partially corrected by a low 
fat diet (Table 1) without corneal arcus or tendinous xan-
thomata. The variant p.Ser465Leu was also identified in 
one of the proband’s daughters (II.2).
To predict the effects of the substitutions we used 
four different in silico algorithms suggesting that the 
p.Ser465Leu variant could affect the functionality of the 
protein: Polyphen (http://genetics.bwh.harvard.edu/
pph2) returns the result Probably damaging (score 1.00 
at Hum Div and 0.045 at HumVar); SIFT (http://sift.jcvi.
org): Not tolerated (score 0.02); Mutation taster (http://
www.mutationtaster.org): Disease causing (score 3.95); 
PMut (http://mmb.pcb.ub.es/): Pathological. BLASTP 
analysis confirmed that the amino acid residue involved 
in the substitution is conserved in 15/16 species. These 
algorithms cannot predict the GOF or LOF effect and it has 
been reported that predictions of GOF mutations should 
be interpreted with caution [7]. To assess the effects of the 
variant, two assays were performed to quantify the resid-
ual LDLR activity and the LDLR amount on the surface 
of patient’s cells as an indirect evaluation of the PCSK9 
effect. In fact, PCSK9 is secreted into the plasma and 
binds directly to LDLR on the cell surface; then, following 
endocytosis, it triggers LDLR degradation [3].
Peripheral blood mononuclear cells were isolated 
from patients and controls and incubated for 48  h in a 
medium with lipoprotein deficient serum (in order to up-
regulate LDLR) supplemented with ionomycin plus PMA 
to stimulate T-lymphocytes. Residual activity of LDLR 
was evaluated by measuring the binding and uptake of 
a fluorescently labeled LDL (1,19-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate-conjugated 
LDL, Life Technology, Foster City, CA, USA), namely DiI-
LDL, incubated with the cells for 3 h at 37°C as previously 
described [8]. Amount of LDLR protein on the cell surface 
was evaluated by measuring the binding of an anti-LDLR 
antibody (Progen Biotechnik, Heidelberg, Germany) on 
stimulated T-lymphocytes. Cells were collected and incu-
bated at 4°C for 1 h with the primary antibody diluted 1:20 
followed by an incubation at 4°C for 45 min with the second-
ary FITC conjugated anti-rabbit antibody (BD Biosciences 
San Jose, CA, USA) diluted 1:200. Fluorescence intensities 
were measured with the FACSCanto (Becton-Dickinson, 
Table 1 Serum lipid profile of the patients.
  I.1a   Proband (I.2)a   II.1a   II.2a   Proband (I.2)b  II.1c   II.2c
Total cholesterol, mmol/L  4.2   11.6   6.5   6.2   4.8   5.7   5.9
LDL-cholesterol, mmol/L   2.5   8.4   4.3   4.6   2.3   3.7   4.1
HDL-cholesterol, mmol/L   1.1   1.5   1.4   1.4   1.3   1.5   1.5
Triglycerides, mmol/L   1.2   3.7   1.6   0.6   2.6   1.1   0.5
ApoB, g/L   0.81   1.97   not available  not available  0.9   1.00   1.00
LDL score (sdLDLd/LDL)   not available  37.1%   not available  not available  not available   4.2%   3.9%
aValues in absence of therapy; bValues after 3 years of therapy with simvastatin plus ezetimibe; cValues during a low fat diet; dsdLDL, small 
dense LDL; percentage of small dense LDL/total LDL were determined as described in Gentile et al. [4].
PCSK9 wt/p.Ser465Leu
I.1 I.2
APOB p.Arg3558Cys/wt
II.1
PCSK9 wt/p.Ser465Leu
II.2
APOB p.Arg3558Cys/wt
Median of fluorescence intensity (DiI-LDL)=122
Residual LDLR activity=42%
Median of fluorescence intensity (antibody)=2008
LDLR amounts on cell surface=122%
Median of fluorescence intensity (DiI-LDL)=173
Residual LDLR activity=60%
Median of fluorescence intensity (antibody)=1633
LDLR amounts on cell surface=99%
Figure 1 Pedigree of the FH family.
The proband is indicated by an arrow. White and gray symbols indicate heterozygosity for PCSK9 mutation p.Ser465Leu. Heterozygosity for 
p.Arg3558Cys mutation in APOB is indicated by symbols in black and white. Residual LDLR activities were calculated based on a mean of 
median fluorescence intensities of the cells from two controls equal to 287; the LDLR amounts were calculated based on a mean of median 
fluorescence intensities of the cells from two controls obtained with anti-LDLR antibody equal to 1643.
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Franklin Lakes, NJ, USA) flow cytometer. LDLR activity or 
amount of LDLR protein on the cell surface was calculated 
as the ratio between the median fluorescence intensity of 
the patients’ cells and the mean of median fluorescence 
intensities of the cells from two controls.
LDLR residual activity in the proband (I.2) and her 
daughter (II.2) who both bore the c.1394C > T variant, was 
42% and 60%, whereas the amounts of LDLR protein on 
the cell surface were 122% and 99%, respectively (Figure 1).
The decreased LDLR activity observed in both the 
proband and her daughter (42% and 60%, respectively) 
together with a small increase or normal LDLR amounts 
could indicate the dysfunction in LDLR endocytosis as 
the cause of increased levels of LDL cholesterol in both 
the mother and the daughter. Our results do not support 
a pathological role of the new PCSK9 variant, although it 
cannot be ruled out because a defect in endocytic pathway 
could mask its effect, since endocytosis is required for its 
action as recently described [9]. In addition, other mecha-
nisms of PCSK9 action unrelated to LDR can be responsi-
ble for increased cholesterol levels [10].
Furthermore, since the proband’s daughter II.1 showed 
hypercholesterolemia without mutations in PCSK9, the 
genetic screening was extended to the LDLR and to all the 
29 exons with intron-exon boundaries of APOB gene. A 
mutation in exon 26 of the APOB gene (c.10672C > T/p.Arg-
3558Cys) was identified in this patient and successively in 
her father (I.1) who showed a normolipidemic profile.
The p.Arg3558Cys mutation in the APOB gene was 
previously described as pathogenic for FH and associated 
with a decreased receptor binding affinity of LDL ranging 
from 30% to 70% and with a high variability of total cho-
lesterol levels ranging from 4.2  mmol/L to 10.9  mmol/L 
[11]. The above findings are supported by our observa-
tions, since p.Arg3558Cys mutation is associated with a 
normal lipid profile in the patient I.1, but at the same time 
it is associated with a mild hyperlipidemic profile in the 
patient II.1.
In conclusion, the new variant p.Ser465Leu in PCSK9 
is not associated to a decreased LDLR amount on the cell 
membrane and does not explain the reduced LDL activity 
which is the cause of the FH phenotype. This case report 
highlights the importance of a deep study of genetic vari-
ants before claiming their pathogenicity.
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